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Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) on Staphylococcus aureus play roles in attachment, invasion and 
immune evasion. It has been previously reported that bone sialoprotein-binding 
protein (Bbp) binds to human fibrinogen. Herein, we show that Bbp and SD-
repeat protein E (SdrE) are allelic variants whose in vitro fibrinogen binding 
profile provides a rationale for the epidemiological presence of Bbp and SdrE in 
human and animal Staphylococcal strains. Epidemiological studies show that 
bbp is found in 32% of human staphylococcal strains, whereas it is nearly absent 
from animal staphylococcal strains.  We show through basic and advanced in 
vitro biochemical techniques that Bbp shows a vastly higher affinity for human 
fibrinogen than SdrE and that Bbp specifically displays affinity for fibrinogen 
from humans.  In contrast, SdrE shows varying affinity for fibrinogen from a 
wide array of various animals.    
The structural basis for this difference is elucidated by determining the 
molecular structures of Bbp and SdrE with no ligands as well as the molecular 
structures of Bbp and SdrE in complex with a peptide representing the 
fibrinogen ligand binding sequence. Data from these structural analyses were 
used to inform mutational analysis of the recombinant proteins, both to confirm 
the integrity structural models and to discover which residues are responsible for 
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the differences in binding profile.  From these data, we show that the Lock 
Regions of the two proteins are a major cause of this difference in binding profile 
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Abs280, Abs450: Absorbance at 280 nm or 450 nm  
Bbp: BSP-Binding Protein 
BSA: Bovine Serum Albumin 
BSP: Bone Sialoprotein 
CA-MRSA: Community Acquired – MRSA  
CD: Circular Dichroism 
ClfA: Clumping Factor A 
ClfB: Clumping Factor B 
DAP: Daptomycin 
DAP-R: Daptomycin Resistant 
DNA: Deoxyribonucleic Acid 
ECM: Extracellular Matrix 
ELISA: Enzyme-Linked Immunosorbent Assay 
Fg: Fibrinogen 




FnbpA: Fibronectin-binding Protein A 
FnbpB: Fibronectin-binding Protein B 
HA-MRSA: Hospital Acquired – MRSA 
IPTG: Isopropyl β-D-1-thiogalactopyranoside 
ITC: Isothermal Titration Calorimetry 
IV: Intravenous 
LA-MRSA: Livestock Acquired – MRSA 
MRSA: Methicillin-Resistant Staphylococcus aureus 
OE-PCR: Overlap Extension – Polymerase Chain Reaction 
PBP2: Penicillin Binding Protein 2 
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
RNA: Ribonucleic Acid 
SDM: Site Directed Mutagenesis 
SEC: Size Exclusion Chromatography 
SPR: Surface Plasmon Resonance (Biacore) 
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TSS: Toxic Shock Syndrome 
TSST-1: Toxic Shock Syndrome Toxin-1 
VISA: Vancomycin-Insensitive Staphylococcus aureus 






TABLE OF CONTENTS 
Page 
CHAPTER I  INTRODUCTION ............................................................................... 1 
Staphylococcus aureus ......................................................................................... 1 
Livestock Acquired – Methicillin Resistant Staphylococcus aureus .................. 9 
MSCRAMMs ....................................................................................................... 13 
Classifying and Monitoring Staphylococcus aureus ......................................... 25 
CHAPTER II  MATERIALS AND METHODS ..................................................... 28 
Commercial Reagents ....................................................................................... 28 
Methods .............................................................................................................. 29 
CHAPTER III  EPIDEMIOLOGY OF ALLELIC VARIANTS SDRE/SDRE1 AND 
BBP/SDRE2  .......................................................................................................... 37 
Introduction ....................................................................................................... 37 
Results ............................................................................................................... 40 
Discussion .......................................................................................................... 52 
CHAPTER IV  FIBRINOGEN BINDING PROFILE OF SDRE1 AND SDRE2 
GIVES A RATIONALE FOR OBSERVED EPIDEMIOLOGY ............................... 57 
Introduction ....................................................................................................... 57 
Results ................................................................................................................64 
Discussion .......................................................................................................... 79 
CHAPTER V  STRUCTURAL BASIS FOR DIFFERENCES IN FIBRINOGEN 
BINDING PROFILE OF SDRE1 AND SDRE2 ...................................................... 81 
Introduction ....................................................................................................... 81 
Results ............................................................................................................... 83 
Discussion ........................................................................................................ 105 
 x 
 
CHAPTER VI  BBP/SDRE2 AND BONE SIALOPROTEIN BINDING .............. 109 
Introduction ..................................................................................................... 109 
Results .............................................................................................................. 113 
Discussion ........................................................................................................ 140 
CHAPTER VII  SDRE1 BINDS FACTOR H ........................................................ 142 
Introduction ..................................................................................................... 142 
Results .............................................................................................................. 146 
Discussion ........................................................................................................ 156 
CHAPTER VIII  CONCLUSION AND FUTURE DIRECTIONS ......................... 160 
Conclusion ........................................................................................................ 160 
Putative Staphylococcal Vaccine Target For Animals ..................................... 169 
Other Implications For Future Research ........................................................ 170 





LIST OF FIGURES 
 
Page 
Figure 1-1. Host Adaptation in LA-MRSA CC398. ................................................ 12 
Figure 1-2. Schematic of Fibrinogen-binding MSCRAMMs. (M. Höök) .............. 15 
Figure 1-3. Dock, Lock and Latch Mechanism. (G. Vannakambadi) ................... 24 
Figure 3-1. Schematic of Sdr Family of MSCRAMMs. (V.Vazquez) .................... 38 
Figure 3-2. Dendogram showing similarity in Sdr family of MSCRAMMs .......... 42 
Figure 3-3. Locating regions of high variation in sdrE......................................... 43 
Figure 3-4. Frequency of sdrE alleles. .................................................................. 45 
Figure 3-5. Dendogram of sdrE1 and sdrE2 from Staphylococcus aureus  
isolates from humans ............................................................................................49 
Figure 3-6. Allelic Frequencies in human and animal staphylococcal isolates. ... 51 
Figure 3-7. Dendogram of sdrE1 and sdrE2 from S. aureus isolates from  
animals .................................................................................................................. 53 
Figure 4-1. Bbp/SdrE2 binds Fibrinogen Aα (V. Vazquez) .................................. 58 
Figure 4-2. Coagulation Cascade .......................................................................... 59 
Figure 4-3. Fibrinogen Structure .......................................................................... 61 
Figure 4-4. SdrE1 and SdrE2 bind Human Fibrinogen. ....................................... 65 
Figure 4-5. Fibrinogen Peptide Inhibition of SdrE binding fibrinogen. ..............66 
Figure 4-6. Isothermal Titration Calorimetry Measurement of SdrE1 and     
SdrE2 binding Fibrinogen Peptide  ..................................................................... 68 
Figure 4-7. SPR measurement of the SdrE-Fibrinogen Interaction. ................... 70 
 xii 
 
Figure 4-8. SdrE1 and SdrE2 binding to animal fibrinogen................................. 72 
Figure 4-9. SPR measurements of animal fibrinogen binding by SdrE1 or 
Bbp/SdrE2. ............................................................................................................ 74 
Figure 4-10. Cow Fibrinogen Peptide Inhibition. ................................................. 77 
Figure 4-11. Animal Fibrinogen Peptide Inhibition. ............................................. 78 
Figure 5-1. Apo-SdrE2-N2N3 and SdrE2-N2N3-Fg Peptide Co-Crystal. ........... 84 
Figure 5-2. Mutational Analysis of the Fibrinogen Target Site.. .......................... 87 
Figure 5-3. Peptide Inhibition of SdrE2 - Fibrinogen with T585V Mutant. ....... 89 
Figure 5-4. Loss of function mutations in SdrE2. ................................................. 91 
Figure 5-5. Ligand Binding Trench of SdrE2-N2N3............................................. 92 
Figure 5-6. Animal Fibrinogen Binding of SdrE2 Chimeric Point Mutants. .......94 
Figure 5-7. SdrE Lock-Latch region alignment. ...................................................96 
Figure 5-8. SdrE2-Lock Chimera binds fibrinogen from animals. ...................... 97 
Figure 5-9. ITC measurement of SdrE2-LockChimera binding human   
fibrinogen peptide ................................................................................................ 98 
Figure 5-10. SPR measurement of SdrE2-LockChimera binding coated 
fibrinogen from various species. ......................................................................... 100 
Figure 5-11. Summary of SPR data. ..................................................................... 101 
Figure 5-12. Structure of SdrE1-N2N3-Fg Co-crystal. ........................................ 102 
Figure 5-13. SdrE1-LockChimera animal fibrinogen binding profile. ................ 104 
Figure 6-1. Attempts at BSP peptide inhibition of SdrE-Fibrinogen. ................. 115 
Figure 6-2. Attempts at BSP peptide inhibition of SdrE-Fibrinogen. ................. 117 
Figure 6-3. Peptide inhibition of SdrE-Fibrinogen with chimeric peptide. ....... 118 
 xiii 
 
Figure 6-4. ITC measurement of SdrE2-N2N3 binding WT and Chimeric 
Peptide. ................................................................................................................ 120 
Figure 6-5. Chimeric Peptide Inhibition of SdrE2-N2N3–Human Fibrinogen . 122 
Figure 6-6. Lock-Latch Region Alignment of SdrE2 .......................................... 124 
Figure 6-7. Bone Sialoprotein binding. ............................................................... 126 
Figure 6-8. Attempts at Peptide Inhibition of SdrE2-Rydén. ............................ 128 
Figure 6-9. SDS-PAGE/Coomassie. .................................................................... 129 
Figure 6-10. Size Exclusion Chromatography of SdrE2-Rydén. ........................ 131 
Figure 6-11. SdrE-Rydén SEC Repeat. ................................................................ 132 
Figure 6-12. Fibrinogen and Bone Sialoprotein binding by SdrE-Rydén. ......... 134 
Figure 6-13. Peptide Inhibition of Wild Type SdrE-N2N3 ................................. 135 
Figure 6-14. Peptide Inhibition of SdrE2-Rydén Monomer. .............................. 137 
Figure 6-15. Peptide Inhibition of SdrE2-Rydén Dimer. .................................... 139 
Figure 7-1. SdrE1-N2N3 binds Factor H, while SdrE2-N2N3 does not. ............ 148 
Figure 7-2. SPR measurement of SdrE1-N2N3 and SdrE2-N2N3 binding     
Factor H. ............................................................................................................... 151 
Figure 7-3. SdrE2-LockChimera binds Factor H similarly to SdrE1-N2N3. ...... 152 
Figure 7-4. Putative Factor H binding site does not inhibit SdrE–Fibrinogen.. 154 
Figure 7-5. SdrE1 and Bbp/SdrE2 binding to Factor H fragments. ................... 155 





LIST OF TABLES 
 
Page 
Table 1-1. MSCRAMMs and their multiple ligands. ............................................. 17 
Table 2-1. List of peptides used in these studies. ................................................. 30 
Table 4-1. Corresponding Animal Fibrinogen Sequences. ................................... 73 
Table 4-2. Binding Parameters calculated from SPR Experiments. .................... 75 
Table 5-1. SdrE2 Mutational Analysis .................................................................. 89 
Table 6-1. Bone Sialoprotein - Fibrinogen Chimeric Peptides ........................... 122 







Staphylococcus aureus is a non-motile, Gram-positive bacterium that 
colonizes humans and causes a wide array of pathology. It was first isolated by 
surgeon Sir Alexander Ogston from the pus of surgical abscesses. Ogston used 
eggs to isolate cultures of the bacteria and then recreated the abscess phenotype 
in rabbits. When he reported his findings in 1880, he named the bacteria 
Staphylococcus.1 It derives its name from its microscopic appearance as a cluster 
of grapes and its macroscopic golden coloring. As with other Gram-positive 
bacteria, S. aureus has a thick cell wall composed of peptidoglycan and 
lipoteichoic acid. S. aureus is differentiated from other Gram-positive bacteria 
such as Streptococci and Enterococci by the presence of the enzymes catalase 
and coagulase. While S. aureus is an aerobic bacterium that grows best in 
temperatures found in the human body, 30-37 °C, it is capable of surviving in a 
variety of environments including conditions of low oxygen, high osmotic 





Staphylococcus aureus in human pathogenesis  
At any given moment, 30-50% of the US population is colonized with S. 
aureus. 20-30% of the population are consistent carriers, while the remaining 
subset is composed of intermittent carriers. Carriers display increased risk for 
diseases caused by the bacterium. S. aureus most frequently colonizes the 
anterior nares, skin and nails.2 It is an opportunistic pathogen; once the outer or 
initial host defenses are compromised, a diverse set of pathologies can result. 
These pathologies range from generally benign skin infections such as boils and 
furuncles to potentially lethal conditions including necrotizing fasciitis and 
pneumonia. Patients with comorbidities such as diabetes, acquired 
immunodeficiency syndrome (AIDS), or recent invasive medical procedures are 
at still greater risk of infection.2  
S. aureus infections are frequently grouped by their source location: 
healthcare-associated MRSA (HA-MRSA), community-associated MRSA (CA-
MRSA), and the newer finding of healthcare-associated with a community onset 
MRSA. Historically, MRSA infections have largely been attributed to HA-MRSA, 
but the incidence and proportion of CA-MRSA has been steadily increasing over 
the past decade.3 In North America and parts of Latin America, this can be 
correlated directly with the rise of the USA300 strain, the spread of which has 
reached pandemic proportions.4 The virulence of the USA300 strain resulted in 
MRSA being the leading cause of death in the United States in 2005 by an 
infectious agent, surpassing HIV/AIDS.5 A recent epidemiological study of 
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MRSA in Canada found that CA-MRSA increased from 19.7% of MRSA infections 
in 2007 to 36.4% of infections in 2011.6  
S. aureus displays the remarkable ability to cause disease in broadly 
different organs and tissues. One of the most common types of infection caused 
by S. aureus is skin and soft tissue infections (SSTIs), which include folliculitis, 
furunculosis and abscesses. The growing incidence of MRSA SSTIs is correlated 
to the spread of CA-MRSA and has resulted in an increase in number of patient 
visits to emergency departments with SSTIs; severe SSTIs such as necrotizing 
fasciitis require both immediate treatment with the broad spectrum antibiotics 
that include MRSA coverage.7 While broad spectrum antibiotics can be 
administered over short periods of time to manage emergent cases, antibiotic 
selection for the long term management of recurrent SSTIs is difficult due to the 
need to balance concerns about antibiotic resistance, long term side effects, and 
efficacy. Consistent decolonization is the goal, but clearance of the bacteria is 
frequently only temporary. 
S. aureus is also a major causative agent of osteomyelitis across all age 
groups and comorbidities. While osteomyelitis infections contain multiple 
pathogens a majority of the time, Staphylococcus aureus is the leading cause 
and is found in 50-70% of osteomyelitis cultures. The rise in methicillin-
resistant S. aureus (MRSA) incidence has been cited as the biggest epidemiologic 
challenge in osteomyelitis and osteoarticular infections. The route of infection 
varies by age.8 In pediatric patients, secondary spread via a hematogenous route 
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is the most common route. However, in adults the most common routes are 
primary infection due to trauma or surgical procedures or secondary infection 
from local spread from a SSTI. One notable exception is the seeding of 
osteomyelitis of the spine in adults, which most frequently occurs via 
hematogenous route.  
Chronic or recurring osteomyelitis is another challenge posed by MRSA 
infection of bone tissue or orthopedic implants. In these settings, the generation 
of a biofilm is often the underlying cause of reduced bacterial clearance. Biofilm 
forms via the deposition of an extracellular matrix composed of proteins, 
carbohydrates and nucleic acids, creating a protected environment for the 
bacteria. Biofilms also pose grave challenges in treatment due to significantly 
higher resistance to antibiotics; it has been estimated that bacteria in a biofilm 
require levels of antibiotics an order of magnitude higher or greater to be 
effective. In the case of prosthetic device or orthopedic implant, the synthetic 
material must often be removed.9 
MRSA pneumonia has represented a serious health threat for many years. 
HA-MRSA presents one of the more difficult challenges in infectious disease due 
to the difficulty in adequately sterilizing hospital equipment such as mechanical 
ventilators. By 2002, a new trend was observed of MRSA pneumonia 
increasingly caused by CA-MRSA strains instead of solely being the realm of HA-
MRSA. Specifically, the rapid spread of the USA300 strain in the community was 
altering the course of the typical infection. CA-MRSA is now recognized as 
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causing a rapidly progressing, frequently fatal necrotizing pneumonia. It is 
characterized by diffuse inflammation, vascular leakage, and severe tissue 
destruction in the host lungs. Unfortunately, epidemiological studies of the 
spread of CA-MRSA pneumonia are difficult to significant variations across 
regions.10   
In addition to causing an array of pathologies by dissemination and 
seeding of different organs, S. aureus is capable of pathogenesis via exotoxin 
production. S. aureus is the second leading cause of gastroenteritis. S. aureus 
gastroenteritis is classified according to the presence of 7 known enterotoxins 
(staphylococcal Exotoxins A-H).11 This exotoxin-based disease is notable for its 
rapid onset, ranging from 0.5 to 8 hours after ingestion of the contaminated 
source, as well as nausea, cramps and diarrhea. While there are few deaths in 
wealthy nations from this disease, the prevalence of the disease warrants further 
research and monitoring.12  
Furthermore, S. aureus also causes Toxic Shock Syndrome (TSS) via the 
pyrogenic superantigen termed Toxic Shock Syndrome Toxin-1 (TSST-1). TSST-1 
functions by binding to the α-chain of MHC Class II via a specific orientation 
that results in the activation of the T-cell receptor despite the absence of its 
specific ligand. This causes a broad, dramatic, non-specific activation of CD4 and 
CD8 T-cells which results in a large release of interleukin-1, interleukin-2 and 
TNFα. The rapid increase of these signals causes a strong acute phase reaction 
including high fever, low blood pressure, malaise and coma.13 While Toxic Shock 
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Syndrome is traditionally associated with improper use of feminine hygiene 
products, TSS is also growing problem in pediatric burns where it causes 
unexpected deaths in patients. Recently, pediatric burn TSS have become the 
most common subtype of this syndrome.14  
Infective endocarditis is another disease that can be caused by S. aureus. 
Traditionally, S. aureus endocarditis is a right sided endocarditis that is 
associated with IV drug abuse as this provides a direct route of entry from 
contaminated skin to the heart valve. This form of infective endocarditis has high 
morbidity and mortality with mortality rates seen in the range of 20-30%.15 
Similar to osteomyelitis and orthopedic implant infection, S. aureus can colonize 
and infect both native valves and prosthetic valves. In cardiovascular implant 
infection, the coating of implants with serum factors such as fibrinogen and 
fibronectin allow for targeting by S. aureus adhesins. The bacteria can 
subsequently form a biofilm on the implanted material that results in an 
infection that is significantly more difficult to treat. In most cases, the implanted 
heart valve must be removed because it is not possible to safely raise serum 







Multifaceted antibiotic resistance in MRSA 
S. aureus infections are frequently difficult to treat clinically due to the 
wide and variable profile of antibiotics against which the bacteria have gained 
resistance. S. aureus epidemics have occurred in waves directly correlated to the 
generation and spread of antibiotic resistance mechanisms by the bacteria. The 
first wave occurred when penicillinase-containing S. aureus reached pandemic 
levels in both hospital and community settings in the 1950s. Methicillin, a 
semisynthetic molecule that is derived from penicillin but resistant to 
penicillinase, was developed to combat this wave and did so effectively for a 
time. However, the next epidemic wave of S. aureus occurred less than a year 
after the introduction of methicillin because of the spread of a new resistance 
gene - penicillin binding protein 2 (pbp2). This methicillin-resistant S. aureus 
epidemic wave was restricted to Europe, but was then replaced in the 1980s by 
novel MRSA lineages that lead to the global pandemic that is seen today.17  
Methicillin resistance is now carried on a mobile genetic element called 
the Staphylococcal Cassette Chromosome mec (SCCmec). There are a variety of 
SCCmec element types that range 21 to 67 kb, but they all carry mecA, a gene 
that encodes for PBP2 and bestows resistance to methicillin and other similar 
cell wall inhibitors upon the bacteria. SCCmec elements also contain ccr genes 
that code for recombinases which allow for the integration and excision of the 
mobile genetic element into and out the S. aureus genome. The categorization of 
SCCmec into types is performed based on the nucleotide sequences of the mecA 
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and ccr genes. Various other genes can be on a particular SCCmec, including 
other virulence factors. Due to this, tracking of the distribution of the different 
SCCmec elements is an important epidemiological goal.  
In addition to methicillin and similar antibiotics, MRSA is resistant to 
erythromycin, clindamycin, ciprofloxacin, tetracycline, and other antibiotics. The 
current drug that is most effective at treating MRSA is vancomycin, a 
glycopeptide cell wall inhibitor. This antibiotic is not ideal for treatment because 
it must be administered via IV due to inefficient gut absorption, must be used at 
high concentrations, and has potential nephrotoxic side effects. Additionally, 
there have isolated case reports of vancomycin-intermediate Staphylococcus 
aureus and vancomycin-resistant Staphylococcus aureus. One of the 
mechanisms by which this resistance occurs is by alteration of the pentapeptide 
sequence is used in cell wall production.  
Another antibiotic that had proved effective against some MRSA strains is 
daptomycin (DAP), which is a lipoprotein that targets the cell membranes of the 
bacteria. Daptomycin usage is restricted by the fact that it is inhibited by 
pulmonary surfactant, making it ineffective against MRSA pneumonia. 
Additionally, numerous recent reports show that mechanisms of daptomycin 
resistance (DAP-R) are emerging and spreading amongst MRSA isolates.18 While 
other options like linezolid, trimethoprim-sulfamethaxazole (Bactrim), and 
tigecycline are available in certain clinical settings, there is a clear need for the 
development of the next generation of antibiotics that will target MRSA.  
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LIVESTOCK ACQUIRED – METHICILLIN RESISTANT 
Staphylococcus aureus 
While Staphylococcus aureus is an opportunistic pathogen that colonizes 
humans, there are members of the Staphylococci genus whose hosts are non-
human species. Staphylococcus gallinarum is observed in avian species such as 
chickens and pheasants, Staphylococcus hyicus is found most frequently in 
bovine species, Staphylococcus lentus occurs most frequently in ovine and 
caprine species, and Staphylococcus intermedius and Staphylococcus 
pseudintermedius are most commonly associated with canine species. Despite 
other members of the Staphylococcus family having adapted to non-human 
species, Staphylococcus aureus is able to colonize and cause disease in a wide 
variety of animals.19  
The ability of S. aureus to spread to other species has become a global 
health issue. While the ability of MRSA to colonize animals has been described 
since 1972, the emergence of clonal complex 398 (CC398) has resulted in the 
widespread epidemic of Livestock Associated–MRSA infections (LA-MRSA) 
across multiple continents and myriad species. The origins of LA-MRSA CC398 
were not clear at first; originally, models that proposed that this represented a 
new bacterial species that combined traits from multiple species of 
Staphylococcus. However, recent data from whole genome sequencing have 
been used to create a phylogenetic reconstruction of the LA-MRSA CC398 clonal 
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lineage. These data show that the origin of this LA-MRSA clonal complex is a 
methicillin sensitive S. aureus strain from humans.20  
The spread of LA-MRSA has led to two major public health concerns. 
First, the rapid spread of this clonal complex has resulted in the presence of drug 
resistant S. aureus in a variety of raw meat products across North America and 
Western Europe. One Dutch study showed that LA-MRSA is present in 12% of 
2217 raw meat samples taken from retail stores in the Netherlands with a range 
of 10-16% varying by animal subset.21 A similar study performed in Iowa, USA 
found LA-MRSA in 16.4% 165 raw meat samples taken from retail stores with a 
6-19% range depending on animal subset.22 
The second major concern is LA-MRSA transitioning from livestock 
species back into humans. The ability of LA-MRSA to colonize the humans who 
handle livestock was first reported in the early 2000s and has been a growing 
problem for livestock handlers and their families.23 There have been isolated 
cases of LA-MRSA occurring in humans who are not in contact with livestock 
animals, but there is no evidence to date that LA-MRSA is able to spread via 
human to human interactions on the larger scale seen with other MRSA 
sequence types. One recent report noted that human-to-human transmission of 
a pig-associated clade of LA-MRSA CC398 contained a unique φ7 bacteriophage 
that is likely example of horizontal transfer between human-associated MRSA 
CC398 and LA-MRSA CC398.24  
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After S. aureus is transferred from humans into a new animal host, S. 
aureus adapts to its new host. There are multiple mechanisms for this 
adaptation. First, S. aureus either accumulates premature stop codons in, or 
completely loses the genes for, virulence factors that are specific to the human 
host (Figure 1-1). This is a reflection of the evolutionary pressure that S. aureus 
and other bacteria face to keep their genomes free of ineffective genes. Examples 
of this include the loss of φSa3, a mobile genetic element in the S. aureus 
accessory genome that contains genes such as chp and scn that regulate the 
human immune system. Uhlemann et al performed whole genome sequencing 
on LA-MRSA S3085, an isolate from pigs, and discovered that MSCRAMMs such 
as clfA, clfB, and fnbpB were truncated.25 In another study of avian 
staphylococcal isolates, it was determined by Lowder et al that the initial strain 
came from humans, made the jump to an avian species approximately 36 years 
ago, and that sPA had accumulated a nonsense mutation.26  
In addition to losing human specific virulence factors, S. aureus bacteria 
that have made the jump to a new animal host also gain virulence factors that 
have been shown to be or are predicted to be virulence factors for the new host. 
An example of this is the presence of φAvβ3 in LA-MRSA CC398 isolates that 
come from raw turkey meat products, but was found only rarely in LA-MRSA 
CC398 isolates from other animals. This prophage contains the SAAV_2008 and 





Figure 1-1. Host Adaptation in LA-MRSA CC398.  
 
 
The underlying mechanism of the acquisition of antibiotic resistance in 
the ST398 clones from animal hosts is related to livestock production practices, 
specifically the food and antibiotics that are given to the animals. The original 
MSSA isolates that made the jump to humans do not show broad antibiotic 
resistance. However, the administration of tetracycline resulted in the selection 
of bacteria positive for the tetracycline-resistance gene tetM. 99% of the 
livestock-associated isolates sampled were positive for tetM, yet none of the 
original human-associated isolates contain them. However, the emergence of 
tetracycline-resistance does not correlate with the emergence of broad multidrug 
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resistance. Broad multidrug resistance has been shown to be achieved when the 
livestock animals are given broad-spectrum cephalosporins; these results have 
spurred the FDA to renew efforts to greatly restrict the use of cephalosporins in 
livestock. Interestingly, a recent publication suggests that the use of metals such 
as zinc in animal feed selects for MRSA CC398 strains. The S. aureus czrC gene 
provides resistance to cadmium, zinc and other metals and was recently found to 
be located on the SCCmec type Vc. This specific SCCmec is present in a majority 
of LA-MRSA CC398 isolates.20,27  
There are a growing number of examples of LA-MRSA CC398 infecting 
livestock handlers. To date, there is little evidence of these bacteria subsequently 
spreading from these patients to other patients. This suggests that by spending 
time in an animal host and adapting to that new host environment, S. aureus has 
reduced virulence in humans. This is likely due to the loss or truncation of 
human specific virulence factors.  
 
MSCRAMMs 
Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) are a class of adhesion proteins that are anchored to the surface 
of Gram-positive bacteria and play a major role in adhesion, as well as other 
roles including host immune modulation and the disruption of hemostasis. 
MSCRAMMs are generally expressed in the log phase of growth, reflecting a role 
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in early adhesion. In contrast, the following stationary phase sees the expression 
of genes like secreted toxins. After expression, MSCRAMMs are targeted for 
secretion via the 30 amino acid signal sequence at the amino terminus of the 
protein. Subsequently, MSCRAMMs are covalently attached to the cell wall by a 
class of enzymes termed sortases. In S. aureus, Sortase A recognizes the LPXTG 
motif on secreted MSCRAMMs, and then enzymatically cleaves this sequence 
between the threonine and glycine residues. After the cleavage event, Sortase A 
attaches the MSCRAMM to the peptidoglycan layer via a transpeptidase 
reaction. This covalent attachment results in the carboxy terminus of the 
MSCRAMMs being attached to the cell wall.28  
With the covalent linkage occurring near the carboxy terminus, the closer 
a domain of an MSCRAMM is to the amino terminus, the farther that domain 
will protrude from the surface of the cell. Moving outward from the cell wall 
anchoring domain, there is a cell wall spanning domain (W) which forms the 
support architecture necessary to display the ligand binding domains at a farther 
distance from the surface of the cell. This role is also accomplished by SD repeats 
(R) and B-repeats in some MSCRAMMs. The ligand binding A domain can 









The presence of the LPTXG motif in MSCRAMMs has allowed for the 
discovery of 22 of the cell wall anchored proteins. The Höök lab is amongst many 
labs that have studied these MSCRAMMs to understand their role in attachment 
and adhesion to host tissues. This work has uncovered numerous host ligands 
that are targeted by MSCRAMMs, including collagen, fibrinogen, fibronectin, 
bone sialoprotein and other proteins of the extracellular matrix. There is a 
surprisingly high level of redundancy in host proteins that are targeted, but the 
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MSCRAMMs frequently target different regions of the same protein. The 
evolutionary pressure the bacteria are under to maintain an efficient genome 
suggests that host ligands that are targeted by more than one MSCRAMM are 
very important for colonization or virulence.  
Interestingly, most MSCRAMMs are capable of binding to multiple host 
proteins (Table 1-1). While there is a clear incentive for the bacteria to have 
multifaceted adhesins on its surface, the development of molecules that are able 
to bind with high affinity via a lock and key method to multiple ligands is 
remarkable from a structural perspective.  
 
FnbpA and FnbpB 
FnbpA and FnbpB are two MSCRAMMs found in S. aureus that are 
named for their ability to bind to the extracellular matrix protein fibronectin 
type I. This binding has been shown to occur through a tandem β-zipper 
mechanism. Both FnbpA and FnbpB also have fibrinogen binding domains that 
are distinct from their fibronectin binding domains; additionally, FnbpA has 
been shown to bind to elastin via its fibrinogen binding site. FnbpA has been 










Over the past decade, the rate of S. aureus infection of these devices has 
grown rapidly. These infections occur because of the ability of S. aureus to first 
bind to the device and then lay down a biofilm. Fibronectin plays a critical role in 
this initial attachment because it is one of the first host proteins to encounter 
and coat the implanted device. After initial attachment to the host protein-
coated device, the bacteria create a biofilm that results in significantly less 
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susceptibility to antibiotics. After the biofilm has matured, S. aureus is dispersed 
to the rest of the body via the circulatory system where it can cause a host of 
secondary diseases.30 
 Interestingly, variations within fnbpA have been found in isolates patients 
who develop S. aureus endocarditis, but not in isolates from similar patients who 
are colonized with the bacteria without developing invasive disease. These 
polymorphisms have been shown to affect the affinity of FnbpA for fibronectin.31 
 
ClfA and ClfB 
Clumping factors A (ClfA and ClfB) are a staphylococcal MSCRAMMs of 
the Sdr family that are important virulence factors and are found in virtually all 
S. aureus isolates. Their major role is to target fibrinogen, but they are capable of 
binding many other host proteins. ClfA is one of the most thoroughly studied 
MSCRAMMs and has been shown to be necessary for staphylococcal 
agglutination of plasma. ClfA mediates of S. aureus adhesion to fibrinogen by 
targeting the 17 amino acids at the carboxy terminus of the fibrinogen γ-chain.32 
ClfB targets residues 316-328 of the fibrinogen Aα chain.33 Both ClfA and ClfB 
mediate platelet aggregation in the presence of fibrinogen and play a role in 
infective endocarditis. ClfA has been shown in animal studies to play critical 
roles in infective endocarditis, septic arthritis, kidney abscess formation and 
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septic bacteremia. In addition to proving efficacious in animal models, 
antibodies against ClfA have shown some promise as treatment in humans.34 
Both ClfA and ClfB display additional mechanisms of virulence through 
the targeting of additional host proteins. ClfA has been shown to target Factor I, 
a regulator of the alternative complement pathway, resulting in reduced local 
activation of the host innate immune system.35 Another important mechanism 
by which ClfB benefits the bacteria is in the colonization of humans via its 
binding of Cytokeratin 10.36,37 
 
SdrG 
SdrG is an MSCRAMM of the Sdr family that is only found in 
Staphylococcus epidermidis that has been discovered to bind to fibrinogen. 
SdrG binds to the residues 6-20 of the fibrinogen Bβ chain, an especially 
important site because this is the thrombin cleavage site in the Bβ chain. The 
binding of SdrG to fibrinogen inhibits cleavage by thrombin, resulting in an 
inhibition in the release of fibrinopeptide B and the generation of fibrin for clot 
formation.38 Like S. aureus, S. epidermidis is a bacterium that colonizes humans 
and is an opportunistic pathogen in humans. It has neither the same set of 
MSCRAMMs as S. aureus, nor does it does it display the same degree of 
antibiotic resistance that MRSA has shown. For these reasons, S. epidermidis 
does not cause the variety nor severity of pathology of S. aureus.  
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However, S. epidermidis does have the ability to cause invasive disease. It 
is most noted for its ability to cause biofilm formation and act as an 
opportunistic pathogen in catheters and medically implanted devices.39 SdrG 
contributes to this virulence through its high affinity interaction with fibrinogen. 
Furthermore, the similarity of the ligand binding domain of SdrG to 
MSCRAMMs in S. aureus has helped to elucidate the structural mechanisms by 
which MSCRAMMs of the Sdr family are able to bind to their target ligands.38 
 
SdrCDE Gene Cluster 
Three members of the Sdr family of MSCRAMMs occur next to each other 
in the core genome of S. aureus. These three MSCRAMMs were named sdrC, 
sdrD and sdrE to reflect their proximity in what was originally assumed to be an 
operon. A recent publication has shed light on the regulation of these genes and 
showed them to be independently regulated, strongly suggesting that this is a 
gene cluster instead of an operon. Specifically, it was shown that sdrD 
transcription occurred in response to different stimuli than sdrC or sdrE. 40 
The three MSCRAMMs in this gene cluster share a similar domain 
organization. Starting from the amino terminus, each of these MSCRAMMs with 
a 30 amino acid signal sequence, followed by the ligand binding A domain. Like 
ClfA and ClfB, the A domains of these three MSCRAMMs are divided into the N1, 
N2 and N3 domains. Unlike ClfA and ClfB, each of these MSCRAMMs contains 
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3-5 B-repeats. Specifically, SdrC contains 2 B-repeats, SdrD contains 5 B-
repeats, and SdrE contains 3 B-repeats. The B-repeats function mainly to further 
protrude the ligand binding domain from the surface of the bacteria, but there is 
evidence to suggest that these domains are capable of low affinity interactions 
with the extracellular matrix as well. The B-repeats in SdrF, an Sdr family 
member from Staphylococcus epidermidis, have been reported to be able to type 
I collagen.41 Additionally, the SdrD B-repeats were shown to bind calcium. These 
data also suggest that the binding of calcium brought greater structure to the B-
repeats.42 
Like ClfA and ClfB, there is an R region in each of these three 
MSCRAMMs that is made up of SD repeats that span the cell wall. Finally, there 
is a canonical LPXTG that allows sortase to anchor these proteins to the surface 
of the bacteria. The MSCRAMM Bbp was discovered and named through a 
separate series of experiments, but we propose that it is actually an allelic variant 
of SdrE based on numerous factors covered below (Chapter 2). It has the same 
domain organization as SdrE and is highly similar by amino acid sequence. 
Interestingly, the gene frequencies of the genes of this gene cluster are not 
consistent. sdrC is present in almost all isolates, similar to clfA  and clfB. In 
contrast, sdrD and sdrE show variable frequencies depending on the type of 
infection from which the isolates are sampled.  
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It appears that each of the proteins in the cluster have a different 
function. The Höök Lab has published that SdrC binds to β-neurexin, a protein 
found on the surface of cells of the central nervous system that plays a role in 
cell-cell adhesion and signaling.43 S. aureus is able to cause brain abscesses, 
although this usually represents a secondary infection. The nearly ubiquitous 
presence of sdrC and the fact that most MSCRAMMs bind to multiple ligands 
suggest that there are other ligands for SdrC.  
While a specific ligand has yet to be found for SdrD, multiple reports 
suggest that this MSCRAMM plays a role in attachment to the epithelium. 
Heterologous expression in the non-pathogenic bacterium Lactococcus lactis 
shows that the presence of sdrD allows for bacterial attachment to desquamated 
epithelial cells.44 Desquamated epithelial cells are the most common cell type in 
the anterior nares, a location where S. aureus has been found to be capable of 
consistently or intermittently colonizing. sdrC, clfB and isdA were also found to 
play a role in attachment to this tissue type. Further epidemiological evidence 
suggests that SdrD also plays a role in staphylococcal pneumonia. 
Until recently, sdrE had no known function. It has been suggested that it 
plays a role in the indirect activation of platelets. Also, molecular epidemiology 
studies suggest that it plays a role in invasion of the host. Recently, it was 
published that SdrE interacts with Factor H, a regulator of the alternative 
complement pathway that reduces the local activation of the innate immune 
system. With the established binding of ClfA to Factor I, a protein to which 
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Factor H binds in vivo, it is not surprising that S. aureus has multiple virulence 
factors that target multiple components of this pathway. Specifically, there is a 
clear benefit to be gained by appropriating the immunomodulatory functions of 
Factor I and Factor H in order to blind the host’s innate immune system to the 
bacteria.45  
Bbp was discovered in a search for surface proteins on S. aureus that play 
a role in attachment to bone tissue in osteomyelitis. Further work found that this 
MSCRAMM bound specifically to the bone extracellular matrix component bone 
sialoprotein.46 Additionally, epidemiological studies show that bbp is 
overrepresented in staphylococcal osteomyelitis isolates. Our lab has recently 
shown that Bbp also binds to human fibrinogen, specifically to residues 561-575 
of the fibrinogen Aα chain. 47 
 
Structure-function relationships in the Sdr family of MSCRAMMs: 
The dock, lock and latch model 
One of the defining characteristics of the Sdr family of MSCRAMMs is the 
display of a ligand binding domain away from the surface of the bacterium via a 
stalk like region. This ligand binding domain is made up of two 
Immunoglobulin-like Folds (Ig-like Folds) that are linked by a Linker domain to 





Figure 1-3. Dock, Lock and Latch Mechanism. (G. Vannakambadi) 
 
 
Like the prototypical Ig-like fold, each of the Ig-like folds in the ligand 
binding domains of these MSCRAMMs are made up of β-sheets.48 This 
secondary structure is confirmed by Circular Dichroism, where the distinctive 
profile of a β-sheet is seen, and from solved crystal structures of MSCRAMMs 
like ClfA, ClfB and SdrC. MSCRAMMs of the Sdr family frequently bind to their 
target ligands via the Dock, Lock and Latch model.49  
In Figure 1-3 provided by collaborator Dr. Vannakambadi, the Dock, Lock 
and Latch model is shown with SdrG and a peptide representing the target 
binding site of SdrG on human fibrinogen. In Panel 1, the N2 and N3 domains of 
SdrG are shown in the open conformation connected by the linker domain and 
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the Lock-Latch domain shown in red. These domains form the ligand binding 
trench, which is where the peptide ligand forms the majority of its contact points 
with the MSCRAMM (Panel 2). After the ligand is bound in the trench, the 
flexible Lock domain moves over the ligand and binds to it, placing the 
MSCRAMM in the closed conformation. Finally, the Latch domain inserts into 
the N2 domain via β-strand complementation, fixing the MSCRAMM in the 
closed state.  At this point, the MSCRAMM ligand binding domain is wrapped 
around the ligand while the ligand enters and exits through the trench in the 
middle of the molecule.38  
 
CLASSIFYING AND MONITORING Staphylococcus Aureus 
Previously, Staphylococcus aureus isolates that caused infections were 
collected and the categorized based on Pulse Field Gel Electrophoresis (PFGE). 
This approach relies on the migration of enzymatically digested S. aureus 
genomic DNA through an acrylamide gel. Isolates of different lineages show 
distinct, repeatable banding patterns. PFGE was replaced by Multi-Locus 
Sequence Typing (MLST), wherein 450-500 bp fragments of important 
housekeeping genes are sequenced. In S. aureus, a minimum of seven 
housekeeping genes are used to classify the isolate based on the public database. 
For isolates that are very similar according to PFGE or MLST analysis, spa 
typing and SCCmec typing can provide an increased degree of resolution.50 
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The increasing efficiencies of DNA sequencing, both in terms of speed and 
cost, have resulted in a rich data set of Staphylococcus aureus sequence data 
becoming available over recent years. Where molecular epidemiology previously 
looked at the presence or absence of an established, relatively small set of genes, 
there are exciting new possibilities in the field to track changes in nucleotide 
sequence on a much different scale.  
One way this technology has provided new information is the study of 
whole genome sequences including accessory genomes or mobile genetic 
elements. For example, in Price et al, 85 S. aureus CC398 isolates were gathered 
from a variety of human and animal hosts and then had their whole genomes 
sequenced. These data were analyzed using single nucleotide polymorphism 
(SNP) analysis to create an ancestral tree of the isolates. Importantly, they were 
able to show the one of the most common clonal complexes that causes Livestock 
Acquired – Methicillin Resistant S. aureus, CC398, originated as a human 
isolate that was susceptible to methicillin. They were able to trace changes that 
show adaptation to the animal hosts and resistance to a wide range of antibiotics 
including methicillin. 
Another way in which whole genome sequencing has proven useful is to 
more fully understand the movement of mobile genetic elements such as 
prophages. The prophage φSa3 has been found to contain virulence factors that 
play a role in modulating the human innate immune system; it has also been 
shown to disappear from S. aureus isolates that have jumped from humans into 
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an animal host.  The prophage φAvβ3 has been discovered in MSSA CC398 
isolates taken from turkeys.20 This prophage contains genes that are projected to 
play a role in virulence specific to avian species. Another example of a gain of 
functionality is the sasX gene, which was recently discovered in a study of MRSA 
infections in China and represents a new putative adhesion molecule that plays a 
role in virulence. 51 
In addition to being able to observe gains in functionality in the accessory 
genome, whole genome sequencing also allows to detect for loss of function 
mutations in virulence factors in the core or core variable genome of S. aureus. 
For example, studies have noted the accumulation of stop codons in human-
specific genes, such as clfA, clfB, and hlaB, in isolates taken from animal species 
such as cows.25 While these changes could be monitored through PCR and 
sequencing of the specific genes, whole genome sequencing allows to sort 
through all of the genes to look for changes.   
The growing, powerful capabilities for whole genome sequencing of 
pathogens have resulted in observations regarding which virulence factors play 
putative roles in differing types of infection. In the case of S. aureus, especially 
MRSA, these observations have allowed for greater understanding of antibiotic 




 MATERIALS AND METHODS 
 
COMMERCIAL REAGENTS 
Phusion DNA Polymerase, BamHI, HindIII, Dpn1, T4 Ligase, and their 
requisite buffers were purchased from New England Biolabs. Luria Broth 
powder, agar, imidazole, SigmaFAST OPD kits were purchased from Sigma 
Aldrich. Isopropyl-β-D-thiogalactopyranoside (IPTG) and ampicillin was 
purchased from Gold Bioscientific. 5 mL HisTrap HP, 5 mL HiTrap Q, and 
Sephacryl S-200 16/60 columns were purchased from GE Healthcare. 0.2 μm 
Filters and 10K MWCO Concentrators were purchased from Millipore. Medium-
binding, flat bottom, 96-well Microlon plates were purchased from Phenix 
Research. Human and mouse fibrinogen was purchased from Enzyme Research. 
Cat, cow, dog, pig and sheep fibrinogen were ordered from Sigma. Superblock 
(in Tris-Buffered Saline), Dialysis Cassettes, were purchased from Pierce-
ThermoScientific. Goat-anti-Rabbit-Horseradish-Peroxidase was purchased 
from BioRad. Bovine serum albumin fraction V (BSA) was from Serological 
Proteins, Inc. Peptides were ordered from Biomatik and the HanHong Group.  
Abs280, Abs260/280, 96-well plates were read using a SpectraMax5 
(Molecular Devices).  Surface Plasmon Resonance was performed by Xiaowen 
Liang using a Biacore 3000 (GE Healthcare). Isothermal Titration Calorimetry 
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was performed using a VP-ITC (Microcal/GE Healthcare). The data were 
analyzed using Origin 5.0 software. Nucleotide and Amino Acid sequences were 
analyzed and phylogenetic trees were made using Mega5 software. 
 
METHODS 
Sequence analysis, phylogeny and dendograms 
Nucleotide sequences of sdrE/sdrE1 and bbp/sdrE2 were gathered from 
collaborators and the public database Patric. Sequences were aligned and 
analyzed using Mega5, which was also used for phylogeny analysis and 
dendogram construction.  
 
Recombinant N2N3 constructs 
The N2N3 regions of Bbp and SdrE were cloned according to previously 
described protocols. Briefly, S. aureus genomic DNA was purified from isolates 
containing the requisite genes. Primers were made that allowed the 
amplification of the N2N3 region in PCR. The PCR product was digested with 
nucleases BamHI and HindIII, then ligated into pQE30 vector that was digested 




Table 2-1. List of peptides used in these studies. 
# Sequence Comment 
1 SKQFTSSTSYNRGD Fibrinogen Aα 561-574 
2 SKQFVSSTSYNRGD FgAα-T565V 
3 SKQFTSSTSYYRGD FgAα-N571Y 
4 SKQFTSSTSYNGGD FgAα-R573G 
5 LKRFPVQGG Bone Sialoprotein  
6 LKRFTSSTSYNGRGD BSP-FgChimera 
7 SYSKQFTSSTSYNR Fg Shift (569-572) 
8 LKRFPVQGSSDSS   Bone Sialoprotein Long 
9 LKRFTVQGSSDSS   BSP-Fg Point mutation 
10 LKRFTVQGSSDSR BSP-Fg Point mutation 
11 LKQFTSSTSYNGR BSP-Fg Point mutation 
12 SKRFTSSTSYNGR BSP-Fg Point mutation 
13 SKQFVTSSTTYNRGD Dog Fg 
14 SKQFVSSSTTVNRGG Cow Fg 
15 SKQLVATSKTYNRGDS Cat Fg 
16 SKQTITKTINREGR Pig Fg 
17 SHNMTTTLNYRDG 





The ligated vector was then transformed into E. coli strain XL1-Blue 
(Stratagene) for long term storage. The Bbp and SdrE constructs were made by 
Jenny K. Horndahl and Vanessa Vazquez, respectively, in our laboratory.  
Prior to each expression, the vector was transformed into the E. coli TOP 
3 (Invitrogen) cell line. Subsequently, overnight starter cultures were made from 
a colony taken from the transformation plate, which were then used to inoculate 
1 liter samples of Luria Broth Media containing 100 μg/mL Ampicillin. After 
these cultures reached exponential phase, they were cooled for 30 minutes at 
4°C. Next, cultures were induced with 500 μM IPTG, then incubated at 18°C for 
24-72 hours with shaking. Cultures were then pelleted, washed with 1x PBS, and 
stored at -80°C. 
After thawing, cell pellets were re-suspended in 1x TBS then lysed in a 
French Press or Cell Disruptor, pelleted in an ultracentrifuge, filtered and then 
applied to a Ni2+ HisTrap Affinity column. Gradient elution was accomplished 
with imidazole. Peak fractions were collected, dialyzed into 25 mM Tris (pH 7.9) 
buffer with no salt, then applied to a HiTrap Q Column, where the protein of 
interest was eluted with an increasing gradient of NaCl. To assess the purity of 
resulting protein sample, peak fractions were run on 10% SDS-PAGE and 





SdrE2/Bbp-N2N3 point mutant and chimeric constructs 
Site-Directed Mutagenesis was performed on the SdrE2-N2N3 constructs 
to create a number of point mutants. Briefly, purified sdrE2-N2N3 in pQE30 
was used in a PCR reaction that included forward and reverse primers that 
contained the desired mutation. These primers bound to the wild type construct 
at the desired site of mutation. PCR amplification of the mutated plasmid and a 
subsequent treatment of the PCR product with DpnI removed the starting DNA 
material. The resulting Dpn1-treated PCR product was digested with BamH1 and 
HindIII and then ligated into pQE30. The construct was confirmed by 
sequencing and transformed into E. coli XL1-Blue for long term storage. 
A modified form of Overlap Extension PCR was used to create SdrE1-
LockChimera and SdrE2-LockChimera. Since the Lock region is near the end of 
the N2N3 constructs, a series of primers were designed that would allow for 
replacing the Lock domain with the corresponding Lock domain from the other 
allelic variant. The first primer pairs with the 15 nucleotides before the Lock 
domain and contains an additional 15 nucleotides with the new desired Lock 
region that will not bind to the parent construct. PCR performed with this 
primer and the wild type forward primer resulted in a PCR product that 
contained a truncated N2N3 construct with 15 new nucleotides at the end. The 
next primer paired with the newly mutated nucleotides and also contained a 15 
nucleotide overhang corresponding to the desired sequence. A third primer was 
needed to complete the construct. The same forward primer was used in each of 
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the 3 PCR reactions. The resulting PCR product was digested with BamH1 and 
HindIII and then ligated into pQE30. The construct was confirmed by 
sequencing and transformed into E. coli XL1-Blue for long term storage. 
The same purification protocol was used for mutant constructs.  
 
Rabbit-anti-BbpN2N3 antibodies 
Polyclonal antisera to BbpN2N3 were generated in two rabbits at 
Rockland Immunochemicals under the Fast Production Protocol. IgG was 
purified using protein A-sepharose (ThermoFisher) affinity chromatography. 
Next, the IgG was cleared for crossreactive binding to Sdr proteins before 
positive affinity purification on BbpN2N3 coupled to EZlink beads 
(ThermoFisher). 
 
Animal fibrinogen ELISA-type assay 
Binding of SdrE1, SdrE2 and mutant/chimeric constructs of these 
MSCRAMMs to fibrinogen from various animals was first determined using an 
ELISA-type solid-phase assay. Fibrinogen from humans, dogs, cats, cows, pigs, 
sheep, and mice along with BSA were coated on microtiter wells at 1 μg per well 
overnight at 4°C in bicarbonate (0.1 M NaHCO3) buffer (pH 8.0). The next day, 
the wells were washed with TBS-T (0.1% Tween-20) and blocked with 
Superblock (TBS) for 3 hours at room temperature. Wells were incubated with 
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dilutions of the MSCRAMM (0.1-10 μM). Detection of binding was achieved by 
Rabbit anti-SdrE1-N2N3 or Rabbit anti-SdrE2-N2N3, followed by Goat anti-
rabbit HRP. Finally, the wells were developed with SigmaFast OPD and the 
absorbance was measured at 450 nm with a SpectraMax M5 plate reader 
(Molecular Devices). 
 
Peptide inhibition ELISA-type assay 
Peptide Inhibition ELISA-type Assays are performed similarly to the 
Animal Fibrinogen ELISA-type Assay. Wells are coated overnight with 1 μg per 
well at 4°C in bicarbonate (0.1 M NaHCO3) buffer (pH 8.0). The next day, the 
wells were washed with TBS-T (0.1% Tween-20) and blocked with Superblock 
(TBS) for 3 hours at room temperature. During blocking, 0.5 μM of the 
designated MSCRAMM was incubated with increasing concentrations of the 
designated peptide (2.5 – 50 μM) for 1 hour. Peptides represent the human 
fibrinogen target sequence and the corresponding residues from fibrinogen from 
species including dogs, cats, cows, and pigs.  
Subsequently, the MSCRAMM-peptide mixture was added to the coated 
and blocked microtiter wells. Detection of binding was achieved by Rabbit anti-
SdrE1-N2N3 or Rabbit anti-SdrE2-N2N3, followed by Goat anti-rabbit HRP. 
Finally, the wells were developed with SigmaFast OPD and the absorbance was 
measured at 450 nm with a Thermo Max plate reader (Molecular Devices). 
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Decreased signal is interpreted as the MSCRAMM binding to more peptide and 
thus being unable to bind to the coated wells. 
 
Isothermal titration calorimetry 
Isothermal Titration Calorimetry (ITC) was performed with a VP-ITC 
(MicroCal) with SdrE1-N2N3 or SdrE2-N2N3 and previously mentioned 
peptides. The MSCRAMMs were dialyzed into TBS (1x) over 48 hours at 4°C and 
their UV absorbance was measured at 280 nm to in order to accurately  and 
directly measure their concentrations. Final dilution of the MSCRAMM to 15 μM 
was performed with buffer from the last round of dialysis. Peptides were diluted 
from a stock concentration of 10 g/L (~6 μM) to their final concentration (100-
250 μM) using the same buffer from the last round of dialysis. Peptide was 
placed into the syringe and injected into the cell containing the MSCRAMM in 10 
μL intervals every 300 seconds after an initial 5 μL injection. Experiments were 
performed at 30°C with stirring set at 300 rpm, reference power set at 15 and 







Surface plasmon resonance 
Surface Plasmon Resonance (SPR) was performed by Xiaowen Liang 
using a Biacore 3000. Two sensor chips were coated with fibrinogen from 
multiple species. The 4 channels of the first chip were coated with human, cow 
and pig FG as well as a control. The 4 channels of the second chip were coated 
with dog, cat, and sheep fibrinogen and the control. SdrE1-N2N3 and SdrE2-
N2N3, dialyzed into TBS, were injected over the chips for 120 seconds, followed 
by buffer. The Kon and Koff were measured. BIAevaluation software was used to 









Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) are an important class of virulence factors that are found in many 
Gram-positive organisms, including the human pathogen Staphylococcus 
aureus. These surface proteins have a variety of functions including host 
adhesion and immune evasion.  Among the staphylococcal MSCRAMMs is a 
family of proteins termed the Sdr Family.  These molecules derive their name 
from the Serine-Aspartate (SD) Repeats that all members contain.  As shown in 
Figure 3-1, the members of this family have similar subdomain architecture and 
include important MSCRAMMs such as clfA, clfB and the sdrCDE gene cluster. 
Intriguingly, the bbp gene shows high sequence similarity to the Sdr family 








In 1989, it was published by Rydén et al that S. aureus isolates from 
osteomyelitis patients are able to bind bone sialoprotein (BSP).52 Further work 
by these investigators isolated an MSCRAMM as the bacterial surface factor 
responsible for this binding. They termed this MSCRAMM Bone sialoprotein–
Binding Protein, Bbp.53 The interaction between Bbp and BSP was further 
isolated to the nonapeptide sequence, LKRFPVQGG, that occurs in the N-
terminal half of BSP.46 Additional evidence for the proposed role of Bbp in 
staphylococcal osteomyelitis is seen in molecular epidemiological studies that 
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show Bbp to be overrepresented in osteomyelitis strains compared to 
staphylococcal strains from all pathologies. 54 
Our lab recently published that Bbp also binds to human fibrinogen.47 
While many MSCRAMMs are known to bind more than one host extracellular 
matrix (ECM) protein, biochemical screens show that fibrinogen is the only ECM 
protein targeted by Bbp. These screens are ELISA-type assays in which 
microtiter wells coated with ECM components are probed with increasing 
amounts of recombinant Bbp.   
Until recently, the function of SdrE remained unknown. Epidemiological 
studies suggested that sdrE might play a role in invasiveness based on an 
increased frequency in invasive isolates as compared to carriage isolates, but 
offered no predictions regarding ligand or mechanism. Recently, it was 
published that SdrE binds to Factor H, a key regulator of the Alternative 
Pathway of the human complement system.45 The ability of S. aureus to coat 
itself with a complement inhibitor represents a potent putative virulence 
mechanism. This capability has been demonstrated in other bacterial and yeast 
pathogens through virulence factors that specifically interact with Factor H. 
Despite the disparate origins of discovery for SdrE and Bbp, we propose 
here that these are not separate MSCRAMMs but instead are allelic variants. The 
striking similarities between the amino acid sequences have led some 
laboratories to consider Bbp and SdrE the same virulence factor, while others 
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consider them allelic variants. However, the vast majority of the field still 
considers Bbp and SdrE to be independent virulence factors. Interestingly, when 
Bbp and SdrE are treated as allelic variants, their gene frequencies can be 
analyzed for clues as to any potential roles in virulence. The gene frequencies of 
these allelic variants in both animal and human staphylococcal isolates are 
compared and sequence variations are studied.  
 
RESULTS 
Bbp and SdrE are allelic variants 
With the technical capabilities of genome sequencing expanding at a rapid 
rate, there is much richer sequence data available for S. aureus, including whole 
genome sequences. Analysis of the available data shows many pieces of evidence 
that support the hypothesis that sdrE and bbp are indeed allelic variants rather 
than separately expressed virulence factors. First,  sdrE and bbp genes are found 
together in less than 1% of S. aureus isolates. Furthermore, these two genes 
occur in the same location of the core genome of S. aureus. This location occurs 
after sdrC and sdrD in the sdrCDE gene cluster, when both sdrC and sdrD are 
present. 
Beyond chromosomal organization, evidence for the allelic variant 
hypothesis exists at the protein domain architecture of sdrE and bbp. Both 
proteins are members of the Sdr subfamily of MSCRAMMs. All members of this 
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subfamily contain similar subdomain architecture with a ligand binding A 
domain presented from the surface of the cell by a stalk-like repeat (R) region 
and a variable number of B Repeats. Both sdrE and bbp contain A domains 
followed by 3 B-repeats, with the size of the aligned subdomains being 
equivalent. The SD-repeat containing R region is variable in length between sdrE 
genes and between allelic variants. The size of the genes correlates directly to the 
number of SD-repeats and is not indicative of variations within the gene or 
within allelic variants.  
Phylogenetic analysis reveals that bbp and sdrE are more similar to each 
other than the other members of the Sdr subfamily (Figure 3-2). Moreover, they 
are more similar to the neighboring sdrC and sdrD of the sdrCDE gene cluster 
than they are to clfA or clfB. This suggests, that the sdrCDE gene cluster shares a 
common ancestor and that the individual genes likely arrived via gene 
duplication events. The locations of these genes suggest that first with sdrD 








sdrE and bbp are highly similar; they are 87% identical by amino acid 
sequence. Interestingly, there are distinct differences in the rate of variation 
depending on the subdomain. Within the ligand-binding N2N3 domains, sdrE 
and bbp display a more modest 67% sequence identity. However, in the N1 
subdomain and B repeats, there is a 95% sequence identity (Figure 3-3).  
If sdrE and bbp were unrelated virulence factors that simply showed high 
sequence similarity, the variations would be expected to occur at similar rate 





 Bbp / SdrE-2
 SdrE / SdrE-1
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subdomains, N2 and N3, suggests that these two genes are allelic variants that 
originated from a similar ancestor. Mutations likely accumulated in one variant 
that conferred a competitive advantage in at least some of the different host 





Figure 3-3. Locating regions of high variation in sdrE.(Adapted from Ed 




It is surprising to see this distribution of variations between sdrE and bbp 
given that the N2N3 domains are responsible for the effector function of the 
MSCRAMMs. It is more common for mutations to occur in regions whose 
putative roles involve support or architectural purposes while conserving 
residues that are integral for binding or enzymatic function. One possible 
explanation for this observation is that one variant accumulated enough 
mutations that the end result was a gain of functionality in a stepwise manner. 
Another possibility is that these allelic variants provide a redundant function to 
S. aureus, such that there is less evolutionary pressure to conserve this ligand 
binding sequence. This possibility appears to be the most likely in light of the 
published ability of Bbp to bind to fibrinogen with high affinity. S. aureus has 
multiple MSCRAMMs that bind to different regions on fibrinogen with high 
affinity, including ClfA, ClfB, FnBPA and FnBPB.  
While neither bbp nor sdrE are present at the same level as the ubiquitous 
sdrC individually, it is interesting to note that the percentage of isolates that 
have either bbp or sdrE is closer to the rate seen for sdrC. Figure 3-4 shows the 
percentage of isolates that were positive for bbp or sdrE in panels 1 and 2, 
respectively. Panel 3 is a combination of data from reports that treated these 
allelic variants as the same gene and composite totals of the data in panels 1 and 
2. Weighted by the number of isolates used in each study, bbp is found in 31.8% 
and sdrE is found in 55.5% of the 649 total isolates gathered from various 
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settings. These percentages in sum, 87.3%, are similar to the reported values 
from the studies that treated these genes as alleles.55-59 
Another piece of evidence that sdrE and bbp are allelic variants is found 
in a study by Pietro, et al¸of the 4 agr loci that sought to find MSCRAMMs and 
other virulence factors that co-segregated with one or more of the agr loci. Their 
findings included the observations that sdrE co-segregated with agr I and agr II, 








All of these data support the hypothesis that sdrE and bbp are allelic 
variants. Furthermore, the current literature contains at least three publications 
that have cited the high degree of sequence identity as sufficient cause to treat 
these two genes as allelic variants.55-57 However, most epidemiological studies 
still regard them as independent virulence factors.  
One of the reasons this is problematic is that the high degree of nucleotide 
sequence similarity between sdrE and bbp can result in false positives due to 
primer overlap. If sdrE and bbp were widely recognized as allelic variants, 
sdrE+/bbp+ isolates would warrant further investigation to check for false 
positives, gene duplications, mobile genetic elements or other explanations for 
this rare finding. With the misconception persisting of sdrE and bbp as 
individual virulence factors, this scenario for potential error will continue. 
In light of these observations, we propose a change in nomenclature. Due 
to the fact that the location of sdrE and bbp occurs at the end of the sdrCDE 
locus and that sdrE occurs at a higher frequency than bbp, we propose changing 
the name of sdrE to sdrE1 and bbp to sdrE2. Additionally, sdrE2 clarifies this 
gene as a member of the Sdr subfamily. While Bbp was originally named based 
on its ability to bind Bone sialoprotein, the recent finding that this MSCRAMM 




Furthermore, sdrE has already been noted in the literature as being a 
highly polymorphic gene, making the concept of a variant of this gene less 
surprising.60 This change in nomenclature would help future studies by reducing 
confusion between these allelic variants and allow for more accurate 
epidemiological studies. It would be especially interesting to see if there is a 
statistically significant difference in the distribution of these allelic variants 
among different pathologies, locations, and host.  
Later we present evidence that there are significant variations in allelic 
distribution, but there is a large, established publication history of S. aureus  
molecular epidemiology whose data we are not able to fully analyze in depth. 
With the advances in genome sequencing technology, the expectation is for the 
available sequence data to rapidly grow in exponential fashion. While it may not 
be possible to analyze previous data, it is important to change the nomenclature 
as soon as possible before the high throughput technology is fully brought to 
bear.  
 
sdrE1 and sdrE2 are allelic variants that form distinct groups upon 
sequence variation analysis 
The Patric database is a publicly available database of whole genome 
sequences of Staphylococcus aureus isolates. The isolates are gathered from a 
variety of types of S. aureus–induced human pathology and locations across the 
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world. We searched this database  to identify the isolates that contained sdrE1 
and sdrE2 and gathered the nucleotide sequences of these genes. Within the 
isolates, sdrE1 occurs in 57 of isolates and sdrE2 occurs in 16 isolates. When the 
amino acid sequences of sdrE1 and sdrE2 were gathered, a majority of the 
variation was found to occur within the sdrE1 variant pool.  
When these variations are aligned and plotted via Maximum Likelihood 
Phylogeny Tree, there was no overlap between variants; sdrE1 and sdrE2 were 
completely segregated (Fig 3-5). This method is capable of putative evolutionary 
ancestors; however, no ancestor could be identified from the publicly available 
sequences. 
In spite of this, there are clues to the gene ancestry. A greater amount of 
variability exists within sdrE1 relative to sdrE2. This suggests that sdrE1 is the 
ancestral gene and that sdrE2 represents an allelic variant that accumulated 
variations that conferred a strong enough evolutionary advantage that any 
intermediate variants were outcompeted by either sdrE1 or sdrE2.  
The RF122 isolate comes from a bovine S. aureus strain and is the only 
variant sequence seen within sdrE2 alleles. When the lower amount of variation 
seen within sdrE2 is viewed in light of the highly specific, high affinity binding of 
SdrE2-N2N3 with human fibrinogen, it raises the possibility that SdrE2 
























































































Figure 3-5. Continued 
 
 
Differences in allelic frequencies in animal and human 
staphylococcal isolates 
To investigate this possibility we expanded our long-standing 
collaboration with Dr. Ross Fitzgerald. The Fitzgerald lab has acquired a 
collection of S. aureus isolates that were taken from a variety of non-human 
species. Initial PCR studies suggested that sdrE1 was overrepresented, while 
sdrE2 was dramatically underrepresented when compared to their gene 
















































































isolates were gathered from a wide array of species and countries. sdrE1 was 
found in 88% of the isolates while sdrE2  was found in 11% of the isolates. This 
suggests that the mechanism of virulence of these allelic variants could play a 





































Sequence variations in sdrE1 and sdrE2 
The sdrE1 and sdrE2 genes were further analyzed through sequencing of 
the A domains. Figure 3-7 shows a Maximum Likelihood Phylogeny Tree where 
sdrE1 and sdrE2 again segregate completely. This revealed 3-4 major subgroups 
of sdrE1 and 2 major subgroups of sdrE2. One sdrE2 subgroup aligns with the 
RF122 isolate, a known bovine isolate, and consists mainly of other isolates 
taken from a bovine source. Moreover, 75% of the overall isolates that contain 




It is clear from these data that sdrE and bbp are allelic variants. Based on 
data from whole genome sequences and sequencing of sdrE and bbp genes from 
staphylococcal isolates gathered from around the world, we propose a change in 
nomenclature to reflect this finding and to prevent confusion. By treating these 
MSCRAMMs as independent virulence factors, it becomes more difficult to 
gather data regarding the distribution of these genes and the potential role for 











































































































































































































































Interestingly, there is a significant difference in the distribution of sdrE1 
and sdrE2 when animal and human isolates are compared. We hypothesize that 
the difference in gene frequencies is a reflection of evolutionary adaptation to 
new animal hosts. S. aureus is a human pathogen that is able to survive in 
animals hosts, but this broad species tropism results in the loss of human-
specific virulence factors when the bacteria makes the jump to an animal host. 
The overrepresentation of sdrE1 in animal isolates suggests that sdrE1 provides 
a greater capacity for virulence than sdrE2 in animals. The exception to this 
model is bovine species, where it appears that the two variants have a similar 
capacity for virulence. 
As observed in the staphylococcal isolates gathered from humans, there is 
a greater degree of variation within sdrE1 alleles than within sdrE2 alleles. It is 
possible that some of these sdrE1 sub-variants have accumulated mutations that 
provide a greater virulence in its new animal host than the sdrE1 sub-variants 
that occur in staphylococcal isolates from humans.  
 Of particular interest are variations in sdrE1 from CC398, a clonal 
complex that has been identified as one of the primary causes of Livestock 
Acquired-Methicillin Resistant Staphylococcus aureus (LA-MRSA). This clonal 
complex has been well studied with both whole genome sequencing and other 
microbiology techniques.  
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The spread of pathology from this clonal complex in animals makes it 
likely that it is better adapted to the animal host than other isolates. SdrE1 
represents an opportunity to understand host adaptation at the level of a single 




FIBRINOGEN BINDING PROFILE OF SDRE1 AND 




Bbp/SdrE2, BSP and fibrinogen 
Recently, the Höök lab published that Bbp/SdrE2 binds human 
fibrinogen. While the MSCRAMM was named for its ability to bind to bone 
tissue, specifically to Bone Sialoprotein, Bbp/SdrE2 would be one of many 
staphylococcal MSCRAMMs that have  shown the ability to bind multiple 
ligands. In an extracellular matrix ligand screen done through ELISA-type assay, 
the ligand binding N2N3 domains of Bbp showed the ability to bind specifically 
to fibrinogen (Figure 4-1a). In light of the multiple host ligands that are targeted 
by this MSCRAMM and the previous data indicating that Bbp is an allelic variant 
of SdrE, we have called for a change in nomenclature where SdrE will now be 
called SdrE1 and Bbp will now be called SdrE2 . Further experimentation using 
Far Western Blotting and truncation mutants showed that the high affinity 




Figure 4-1. Bbp/SdrE2 binds Fibrinogen Aα (V. Vazquez) 
(A)  Binding of purified N2N3 region of Bbp/SdrE2 to various extracellular 
matrix proteins. (B) Isolation of the target site of Bbp in human fibrinogen using 
Coomassie staining and Far Western analysis. 
 
 
Fibrinogen in hemostasis 
Fibrinogen is a major serum protein and acute phase protein produced by 
the liver that plays a critical role in coagulation as well as roles in inflammation 
and immune defense. The essential step in coagulation results in fibrinogen 
being cleaved by activated thrombin to form an insoluble product termed fibrin. 
In order for prothrombin to be activated to thrombin, a series of enzymatic 
reactions must first occur (Figure 4-2). This cascade results in an amplification 





Figure 4-2. Coagulation Cascade  
 
 
This insoluble fibrin is then cross-linked by Factor XIII to form a mesh-
like network that is capable of stopping the flow of blood, attracting pro-
coagulation platelets, and recruiting immune cells such as neutrophils. Platelets 
and neutrophils display integrin molecules on their surface that recognize 




While normal blood levels of fibrinogen range from 1.5-3 g/L, fibrinogen 
deficiencies can occur congenitally or be acquired. Congenital afibrinogenemia is 
a rare bleeding disorder that occurs at an approximate rate of 1:1,000,000 and 
encompasses mutations that occur in any of the three genes encoding the three 
polypeptide chains of fibrinogen.62 Phenotypically, it presents with spontaneous 
bleeding or excessive bleeding after minor trauma. The low prevalence of 
congenital afibrinogenemia is likely a consequence of the importance of 
fibrinogen in for normal hemostatic function. Acquired fibrinogen deficiency 
generally occurs as a result of blood loss from trauma, disseminated 
intravascular coagulation (DIC), cirrhosis or sepsis. 
 
Fibrinogen structure 
Fibrinogen is a hexameric molecule that is composed of two sets of three 
chains (Fig 4-3) that are linked by disulfide bonds. The two sets of chains are 
connected by a central nodule where the N-termini interact. This region is 
cleaved by thrombin. Progressing towards the C-termini, the subsequent regions 
form coiled-coil structures, followed by a globular domain termed the D 
Domain.63 After the injured site has healed, fibrinogen is enzymatically cleaved 
by the activated form of plasminogen called plasmin. During fibrinolysis by 
plasmin, the D-domains are cleaved. D-dimers are measured clinically as a 
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diagnostic test for DIC and pulmonary embolism, in which fibrin is being cleaved 
rapidly.  
The αC-domain has been of highlighted in the field of fibrin mechanics 
where recent findings implicate αC-domain in playing a prominent role elasticity 
of fibrinogen. Nuclear Magnetic Resonance studies of αC-domain have 
confirmed that this domain is largely unstructured. In these studies, a hairpin 
turn was discovered from amino acids 423-450.64 Moving towards the carboxy 
terminal of this beta hairpin, within a flexible region of the protein, is the 




Figure 4-3. Fibrinogen Structure 
(A) Individual Fg chains, Aα, (blue) Bβ (green) and γ (red), FpA and FpB: 
fibrinopeptides A and B; black bars: disulfide bonds; triple arrows: plasmin cleavage 






Biochemical investigation of Bbp-fibrinogen binding 
The high affinity binding of SdrE2-N2N3 to the Fibrinogen Aα chain was 
investigated through an array of biochemical approaches. In Surface Plasmon 
Resonance experiments, SdrE2-N2N3 showed rapid on and off rates when 
injected over a human fibrinogen coated chip. A linear dilution series was used 
to determine a sub-micromolar dissociation constant (KD = 0.54 μM ± 0.07).  
A putative Fg target site was elucidated via ELISA-type solid-phase assays 
using truncation mutants; from these, a 15 amino acid sequence emerged as the 
target site of SdrE2-N2N3 on Fg. Subsequently, a peptide was synthesized 
(Biomatik) that corresponded to this site. This peptide was able to inhibit the 
binding of SdrE2-N2N3 to Fg-coated wells in ELISA-type solid-phase assay in a 
dose-dependent manner, showing that this site is the primary target of SdrE2-
N2N3 within fibrinogen. Isothermal titration calorimetry was performed with 
this peptide titrated into a cell containing SdrE2-N2N3. By measuring the heat 
given off during the exothermic reaction, a KD = 0.31 μM was calculated. 
It was also shown that SdrE2-N2N3 interacts minimally with fibrinogen 
from other animals. This is especially noteworthy in light of the high degree of 





Putative role in pathogenesis for Bbp-fibrinogen interaction 
The widespread presence and multiple physiological roles of fibrinogen in 
humans make it an excellent target for the opportunistic pathogen 
Staphylococcus aureus. One example of importance of fibrinogen attachment is 
that multiple staphylococcal MSCRAMMs are targeted to this critical coagulation 
factor. Redundancy of function allows for continued pathogenesis despite 
mutations in the host or pathogen. Furthermore, S. aureus virulence factors 
affect fibrinogen via different mechanisms. Coagulase activates prothrombin to 
initiate fibrinogen cleavage. ClfA causes clumping of fibrinogen. ClfB, FnbpA and 
FnbpB are also capable of binding to the multiple chains that make up 
fibrinogen. 
There are two putative mechanisms of virulence in the binding of SdrE2-
N2N3 to fibrinogen. First, it has been shown that the addition of SdrE2 inhibits 
the conversion of fibrinogen to fibrin. The inability of fibrinogen to form clots 
would present a broader opportunity for S. aureus to invade its host. Second, the 
target site of SdrE2-N2N3 contains an integrin-binding RGD motif. Interfering 
with the ability of host cells, such as platelets and neutrophils, to adhere to 







SdrE1 and SdrE2 have significant differences in affinity for human 
fibrinogen 
As previously published, SdrE2-N2N3 binds to human fibrinogen with 
high affinity. Given that SdrE2, formerly Bbp, is an allelic variant of SdrE1 with 
high sequence identity, the ability for SdrE1-N2N3 to bind human fibrinogen 
was tested in ELISA-type solid-phase assay. SdrE1-N2N3 did show the ability to 
bind fibrinogen-coated multititer wells; however, it also displayed a lower 
apparent affinity for human fibrinogen than SdrE2-N2N3 in these experiments 
(Figure 4-4). Although SdrE1 and SdrE2 share 67% amino acid sequence identity 
within their N2N3 domains, there was a 5-fold difference in apparent affinity 
with SdrE1-N2N3 displaying a KD = 0.5 μM and SdrE2-N2N3 displaying a KD = 
0.1 μM. This indirect detection assay is not a highly accurate way to determine or 
compare KD approximations for multiple reasons, chief among them being the 
different primary antibodies used to detect the respective MSCRAMM binding to 





Figure 4-4. SdrE1 and SdrE2 bind Human Fibrinogen. 
 
 
SdrE1 and SdrE2 bind the same target sequence in the fibrinogen Aα 
chain 
In order to confirm that SdrE1 binds human fibrinogen at the same site as 
SdrE2, Peptide Inhibition ELISA-type Assays were performed (Figure 4-5). 
Increasing amounts of the peptide representing the human fibrinogen target 
sequence were pre-incubated with 0.3 μM SdrE1 or SdrE2. As with SdrE2-N2N3, 
SdrE1-N2N3 was inhibited from binding to the human fibrinogen coated wells; 
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however, this inhibition requires a 10-fold higher concentration of peptide to 
inhibit binding by 80%. SdrE2-N2N3 displayed an IC80 = 1.5 μM while SdrE1-
N2N3 displayed an IC80 = 15 μM. These data give more support to a large 










ITC measurements of fibrinogen peptide binding by SdrE1 and SdrE2  
In order to more accurately determine the putative differences in affinity, 
analytical biochemical techniques were used. Isothermal Titration Calorimetry 
(ITC) is beneficial because it provides an accurate measurement of the 
thermodynamic parameters of binding and is the best approach to investigate 
binding of MSCRAMM and ligand peptide in solution. ITC was used to measure 
the affinity of the two allelic variants for both human fibrinogen and the peptide 
representing the human fibrinogen target site. Based on previous data, we 
hypothesized that there would be a significant difference in affinity between 
SdrE1 and SdrE2 for Fg, with SdrE2-N2n3 displaying a significantly higher 
affinity than SdrE1-N2N3.  
When the data were compared for ITC experiments with the allelic 
variants binding the previously described human fibrinogen peptide, SdrE2-
N2N3 displays a 20-fold greater affinity than SdrE1-N2N3 (Figure 4-6). The 
differences in affinity for the peptide are traced to differences in the change in 
entropy between the two interactions. Also, SdrE2-N2N3 having 5 fold greater 
affinity for full length fibrinogen than SdrE1-N2N3 (data not shown). The 
difference in affinities for the peptide compared to full length fibrinogen are 
likely attributed to the greater steric hindrance that the MSCRAMMs must 




Figure 4-6. ITC Measurement of SdrE1 and SdrE2 binding Fibrinogen 
Peptide 
(A) SdrE2-N2N3 binds the peptide representing the target site in human fibrinogen 
with much greater affinity than (B) SdrE1-N2N3 binds the same peptide. The table 







When ClfA-N2N3 binding of full length fibrinogen and a peptide 
representing the binding site in fibrinogen are examined in ITC experiments, 
ClfA-N2N3 was observed to bind to full length fibrinogen better than the 
peptide. Further experimentation confirmed the underlying reason for this 
observation is a secondary fibrinogen binding site outside of the ligand binding 
trench on ClfA-N2N3. Given that both SdrE allelic variants are observed to bind 
to the peptide with a greater affinity than to the full length fibrinogen, as well as 
the N numbers displayed in these experiments, the data suggest that the 
previously elucidated target site is the only major binding site of SdrE in 
fibrinogen.34 
 
SPR measurements of human fibrinogen binding by SdrE1 and SdrE2 
Surface Plasmon Resonance was used to investigate the interactions 
between SdrE1 and SdrE2 and human fibrinogen. It was previously reported that 
SdrE2 binds human fibrinogen coated chips with a KD = 0.54 μM ± 0.07. When 
repeated, we calculate a KD = 1 μM for SdrE2-N2N3 to human fibrinogen. SdrE1-
N2N3 has a KD = 46 μM (Figure 4-7). The affinity of SdrE2-N2N3 for full length 
fibrinogen is similar in both ITC and SPR experiments. However, there is a 7.5-
fold difference between the affinity constants of SdrE1-N2N3 as measured in the 
two techniques. Both experiments were repeated multiple times, leaving us to 
hypothesize that the differences are due to changes in the display of the binding 
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site between coated and soluble fibrinogen. While the magnitude of the 
difference in binding varies by technique, the binding profiles remains consistent 
across each set of experiments. SdrE1-N2N3 displays a lower affinity, broad 
species specificity fibrinogen binding profile while SdrE2-N2N3 displays a high 








SdrE2 has high specificity for human fibrinogen while SdrE1 has 
broad species specificity  
As previously published, SdrE2 binds specifically to human fibrinogen 
with high affinity, but does not interact strongly with fibrinogen from other 
animals (Figure 4-8). The high specificity of SdrE2 for human fibrinogen is 
especially intriguing given the high sequence similarity between the target 
human fibrinogen sequence and the corresponding sequences from some 
animals such as dogs. In all fibrinogen samples from non-human species tested 
here, there is an insertion of a valine (Table 4-1). It appears likely that this valine 
is responsible for changes in binding. 
While SdrE2-N2N3 showed a highly specific binding profile, SdrE1-N2N3 
showed a significantly different profile in ELISA-type assay featuring microtiter 
wells coated with fibrinogen from different species. SdrE1-N2N3 is able to bind 
with varying affinity to fibrinogen from multiple animals. The differing binding 
profiles are particularly noteworthy given the 67% amino acid sequence identity 


















SPR measurements of animal fibrinogen binding by SdrE1 and SdrE2 
SPR experimentation was used to confirm the findings of the animal 
fibrinogen ELISA-type assays. The ability of SdrE1-N2N3 and SdrE2-N2N3 to 
bind to chips coated with fibrinogen from humans, cows, pigs, dogs, cats or cows 
was measured to determine the kinetic parameters of these interactions, 
including KD (Figure 4-9). In addition to its high affinity interaction with human 
fibrinogen, SdrE2 was able to interact with cow fibrinogen, but with a 20-fold 
lower affinity compared to the SdrE2-human fibrinogen interaction. In contrast, 
SdrE1 was able to interact with fibrinogen from all animals tested (Table 4-2) 
with affinities ranging from 1.5-fold to 4-fold lower than the affinity of SdrE2 for 





Figure 4-9. SPR measurements of animal fibrinogen binding by 











SdrE1 and SdrE2 bind to the same site in cow and human fibrinogen 
While the ELISA-type assay was not sensitive enough to detect binding of 
SdrE2-N2N3 to cow fibrinogen, there was a measurable interaction between 
these two proteins in SPR experiments. When comparing the target sequence in 
human fibrinogen to the corresponding sequence in cow fibrinogen, there are 
only four changes. Based on the similarities, we hypothesized that the binding of 
cow fibrinogen by SdrE1 and SdrE2 was targeted to this region. To test this, a 
Peptide Inhibition ELISA-type assay was performed wherein 0.5 μM SdrE1 or 
SdrE2 was pre-incubated with an increasing amount of human or cow fibrinogen 
 76 
 
peptide (1.5-60 μM), then added to wells coated with human fibrinogen (Figure 
4-10). The cow fibrinogen peptide was able to inhibit the binding of SdrE1 and 
SdrE2 to human fibrinogen coated wells, but to a lesser degree than the human 
fibrinogen peptide. This provides evidence that the target site in cow fibrinogen 
corresponds to the target site in human fibrinogen. It also corroborates the 
previous data that these allelic variants have a higher affinity for human 
fibrinogen than animal fibrinogen.  
The Peptide Inhibition ELISA-type assay technique was also performed 
using peptides representing the amino acid sequences from other species that 
correspond to the human fibrinogen target sequence (Figure 4-11). SdrE2-N2N3, 
which does not bind to fibrinogen from species other than human or bovine, was 
not inhibited by peptides representing the target site in fibrinogen from dogs, 
cats or pigs. SdrE1-N2N3, which shows a more promiscuous fibrinogen binding 
profile in ELISA-type assays, was inhibited at rates ranging from 20% to 60% by 
the different target peptides. Given that human fibrinogen is still the species for 
which SdrE1-N2N3 shows the highest affinity, it is not surprising that the animal 

















ITC measurements of SdrE1 and SdrE2 binding cow fibrinogen 
peptide 
ITC was used to measure the affinity of the two allelic variants for the cow 
fibrinogen peptide. In SPR experiments using full length cow fibrinogen, a 
similar maximal binding was observed, but a significantly different KD was 
calculated between the two.  In ITC experiments using a soluble peptide 
representing the fibrinogen binding site, SdrE1-N2N3 and SdrE2-N2N3 
displayed a similar affinity. 
 
DISCUSSION 
While SdrE1 and SdrE2 are 67% identical within the ligand binding N2N3 
domains, they have significantly different biochemical profiles with regards to 
fibrinogen binding. SdrE2-N2N3 binds with high affinity and high specificity to 
human fibrinogen, while SdrE1-N2N3 binds with lower affinity to human 
fibrinogen but displays broad species specificity in fibrinogen binding.  
Interestingly, these results give a biochemical rationale for the observed 
gene frequencies of SdrE1 and SdrE2 in human and animal staphylococcal 
isolates (Chapter 2). sdrE1 is present at higher frequencies in animal isolates and 
SdrE1-N2N3 able to interact with fibrinogen from these animals. sdrE2 is 
present at higher frequencies in human isolates as compared to its presence in 
animal isolates and SdrE2-N2N3 shows little affinity for fibrinogen from non-
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human species. An outlier to this framework is the cow. The otherwise human-
specific SdrE2-N2N3 did show an affinity for cow fibrinogen as well as a 
sequence in cow fibrinogen that corresponds to the target sequence in human 
fibrinogen. It is interesting to note that out of the staphylococcal isolates 
gathered from animals that had the sdrE2 gene, 75% were gathered from bovine 
sources.  
From these data, we propose that SdrE2 is an example of adaptation by S. 
aureus to the human host in which accumulated mutations resulted in improved 
binding to human fibrinogen and a loss of binding to fibrinogen from most other 
species. The high affinity demonstrated for fibrinogen by multiple analytical 
biochemical techniques suggests that fibrinogen binding is the main role of 
SdrE.  
It is important to note that there are relatively few changes between sdrE1 
and sdrE2 that resulted in this dramatic change in phenotype. However, within 
the N2N3 domains, there are still 115 differences in amino acid sequence. It is 





STRUCTURAL BASIS FOR DIFFERENCES IN 




The fibrinogen binding profile of allelic variants SdrE1-N2N3 and SdrE2-
N2N3 provide a rationale for the observed epidemiology of their respective 
genes. The magnitude of the differences in binding, as measured with multiple 
techniques, was larger than one would expect in light of the high  degree of 
similarity between the amino acid sequences of the variants. There is 87% 
sequence identity between the genes, including 95% identity outside of the N2N3 
domains and 67% identity within the N2N3 ligand binding domains.  
We hypothesized that mutational analysis, based on structural data 
gathered from the crystal structures of apo- and bound SdrE1-N2N3 and SdrE2-
N2N3, would provide insight into the specific differences between SdrE1 and 
SdrE2 that are responsible for the differences in fibrinogen binding. While the 
residues that are different between the variants are known and could be modeled 
based on the solved crystal structures of other similar MSCRAMMs, true insight 
into the molecular nature of the SdrE1/2-Fibrinogen interaction would require 
experimental data in the form of crystal structures of apo-SdrE1-N2N3, apo-
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SdrE2-N2N3, SdrE1-N2N3-FgPeptide co-crystal, and SdrE2-N2N3-FgPeptide 
co-crystal.  
Towards this goal, recombinant SdrE1-N2N3 and SdrE2-N2N3 were 
expressed and purified. These purified proteins were used in collaboration with 
Dr. Ganesh Vannakambadi who is responsible for crystallization and structure 
solving. Initially, the apo-SdrE2-N2N3 and SdrE2-N2N3-FgPeptide co-crystal 
were solved. Mutational analysis of the target site in fibrinogen and SdrE2-N2N3 
were carried out based on these structures. Recently, the structures of apo-
SdrE1-N2N3 and SdrE1-N2N3-FgPeptide were also solved. To support the 
notion that the differences in fibrinogen binding by SdrE allelic variants are 
driven by a small set of SdrE residues, we generated SdrE1/SdrE2 chimeric 
constructs. We hypothesized that the binding profile of one allelic variant could 
be mimicked by the other variant with relatively few changes to the amino acid 
sequence. Based on solved co-crystal structures, we predicted that a chimeric 
SdrE2 mutant would display the binding profile of SdrE1 – lower affinity for 
human fibrinogen and broad specificity for a variety of fibrinogen species - by 
changing a minimal number of critical SdrE2 to their respective SdrE1 
counterparts. Similarly, with the solved SdrE1-N2N3-Fg structure, we 
hypothesize that a chimeric SdrE1 molecule could be converted to a high affinity 





Crystal structures of apo-SdrE2-N2N3 and SdrE2-N2N3-Fg peptide 
co-crystal 
Dr. Ganesh Vannakambadi solved the structures for apo-SdrE2-N2N3 
and the SdrE2-N2N3-Fg Peptide co-crystal (Figure 5-1). These data show that 
SdrE2 binds to fibrinogen via the Dock, Lock and Latch model in a similar 
manner to other MSCRAMMS. In this model, fibrinogen encounters SdrE2 in 
the open conformation  and enters the ligand binding trench formed by the N2 
and N3 domains of SdrE2. Subsequently, the Lock domain closes the 
conformation by covering the ligand-filled trench. Finally, the Latch domain 
inserts into the N2 domain by β-strand complementation. As seen in Figure 5-1, 
the conformational changes between the open, empty state and the closed, 






Figure 5-1. Apo-SdrE2-N2N3 and SdrE2-N2N3-Fg Peptide Co-Crystal. 
Panel 1 shows SdrE2-N2N3 (yellow) structure when bound to the human fibrinogen 
peptide (blue) that is representing the target site. New, additional β-hairpin shown in 






While SdrE2-N2N3 binds Fg  via the Dock, Lock and Latch model, there 
are a few important differences from previous examples of Dock, Lock and Latch 
binding. There is a small β-hairpin (Fig 5-1, red) that intrudes on the ligand 
binding trench and is not found in other MSCRAMMs. The β-hairpin is seen in 
both the open and closed conformations of SdrE2-N2N3. This creates additional 
contact points with the ligand and causes the ligand to form a heretofore unseen 
twist within the trench (blue). Also, densities were only seen for the residues 
561-573 of the peptide.  
 
Mutational analysis of the target sequence 
Previously, the specific sequence in fibrinogen to which SdrE2-N2N3 
binds was isolated via binding assays with truncation mutants of the fibrinogen 
Aα chain. Through these experiments, residues 561-575 were identified as the 
site of binding. A 15 amino acid peptide representing this binding site was used 
to confirm this finding in Peptide Inhibition ELISA-type assays and ITC.  
SdrE2-N2N3 does not bind to fibrinogen from non-human species with 
the exception of cow fibrinogen. This is particularly noteworthy in light of the 
high degree of sequence similarity between the target sequence in human 
fibrinogen and the corresponding sequences from fibrinogen from other species. 
In order to understand the structural basis for this, peptides were synthesized 
that contained point mutations in the wild type human fibrinogen sequence. The 
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mutations were designed by Dr. Ganesh Vannakambadi based on the solved 
crystal structure of SdrE2-N2N3 in complex with the human fibrinogen peptide. 
A Peptide Inhibition ELISA-type assay was used to assess the relative affinities 
of the mutant peptides for SdrE2-N2N3. It was observed within the structure 
that residues 573-575 (Gly-Asp-Ser) did not appear to be interacting with any of 
the residues within the MSCRAMM. It was hypothesized that a peptide lacking 
these residues would display unaltered affinity for SdrE2-N2N3 in comparison 
to the original peptide. A peptide representing residues Fg Aα 559-572 (“shift”) 
was ordered and tested in the Peptide Inhibition ELISA-type assay (Figure 5-2). 
The resulting inhibition curve was not statistically different from the original 
(WT) fibrinogen peptide. This suggests that GDS residues are not important for 
binding, confirming the hypothesis. 
That SdrE2-N2N3 binding of fibrinogen was effected by minor changes in 
sequence was of particular interest in these studies. The most notable change 
from human fibrinogen to fibrinogen from other species is the insertion of a 
valine at position 575. This insertion is shared by fibrinogen from all species 





Figure 5-2. Mutational Analysis of the Fibrinogen Target Site.  
Peptide inhibition of the ability of SdrE2-N2N3 to bind to human fibrinogen coated 




In order to determine which shifted residues were responsible for a 
reduction in binding, three separate point mutations were made within the 
original fibrinogen peptide: T565V, N571Y, and R572G. Each mutation replaces 
a putatively important wild type residue with the residue that would occur at 
that position with a valine insertion at position 575. Without the solved 
structures, many more mutations would have been necessary to determine 
critical residues. The structural data allowed us to narrow our focus.  
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N571Y showed no difference in binding from the wild type peptide. R572G 
consistently showed a moderate decrease in binding, suggesting that interaction 
with this residue is of some importance for SdrE2-N2N3. The largest difference 
in binding occurred with the T565V mutation, where inhibition was not seen at 
the highest concentration of peptide. This strongly suggests that SdrE2-N2N3 
does not interact strongly with the peptide because it is instead binding to the 
human fibrinogen-coated wells. In a follow-up assay, partial inhibition was 
eventually seen at 1000 times the concentration of MSCRAMM (Figure 5-3); this 
represents a >100-fold lower affinity.  
 
Mutational analysis of SdrE2-N2N3 
The solved structure of SdrE2-N2N3-Fg Peptide co-crystal at high 
resolution reveals the residues in the MSCRAMM and peptide whose close 
proximity strongly suggest an interaction. In order to confirm these interactions, 
mutational analysis of SdrE2-N2N3 was performed. Putative residues integral 
for binding were determined by Dr. Ganesh Vannakambadi. Constructs 
containing the point mutations listed in Table 5-1 were made using site-directed 
mutagenesis. Constructs confirmed to have the desired mutations by sequencing 
were transformed and expressed in E. coli, purified through a 2-step affinity 
chromatography process, and then finally tested in ELISA-type assay for binding 








Table 5-1. SdrE2 Mutational Analysis 
Name Purpose 
SdrE2-Y475A Confirm Structure 
SdrE2-A469D Confirm Structure 
SdrE2-D588A Confirm Structure 
SdrE2-D480A Chimeric Mutation 
SdrE2-Y475K Chimeric Mutation 




While the SdrE2-Y575A mutation did not result in any change in 
phenotype, the SdrE2-A469D point mutation did show a partial reduction in 
binding. The most significant change in binding was seen with the SdrE2-D588A 
mutation where there was a total loss of fibrinogen binding (Figure 5-4). This 
residue occurs in the lock region (Figure 5-5) and appears to interact with the 
Q563 residue of the fibrinogen peptide; the Q563 residue has shown to play an 
important role in binding (Chapter 6).  
Interestingly, the D588A mutation results in the same phenotype as seen 
in the SdrE2-ΔLock and SdrE2-ΔLockLatch deletion mutants. These deletion 
mutant constructs were made by Vanessa Vazquez to help elucidate the 
mechanism of SdrE2 binding to fibrinogen. They were purified according to the 
same protocol as the recombinant wild type N2N3 proteins. Subsequently, these 














Figure 5-5. Ligand Binding Trench of SdrE2-N2N3.  
Human fibrinogen peptide (backbone in red, side chains in blue) shown with the SdrE2 
side chains (yellow) that are the shortest distance from the peptide and are the most 
likely to interact. SdrE2-D588 noted with red box; this residue was mutated to an 




No single point mutation creates a chimeric SdrE2 that has the SdrE1 
phenotype 
Using the solved structures of apo-SdrE2-N2N3 and SdrE2-N2N3-Fg 
Peptide co-crystal, SdrE2-N2N3 residues were selected that both have a putative 
role in fibrinogen binding and are different from the corresponding residues in 
SdrE1-N2N3. Point mutations were made in the wild type SdrE2-N2N3-pQE30 
construct using site directed mutagenesis that replaced the SdrE2 residues with 
the corresponding SdrE1 residue. These mutant constructs were then expressed, 
purified and tested in ELISA-type assay for their dose-dependent binding to 
microtiter wells coated with fibrinogen from various species. Representative 
assays are shown in Figure 5-6. None of the mutants showed a phenotype 
resembling SdrE1-N2N3 or the repeatable ability to bind to fibrinogen from 






Figure 5-6. Animal Fibrinogen Binding of SdrE2 Chimeric Point 
Mutants. 
While there were some changes in binding to human fibrinogen, none of the listed point 
mutants were able to replicate the promiscuous binding profile of SdrE1 (red) 
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SdrE2-LockChimera confers SdrE1 phenotype on SdrE2 
Building on the observation that the D588 residue is integral for SdrE2-
N2N3 binding of Fg, the residues surrounding D588 were analyzed. D588 is 
located in the flexible Lock region of SdrE-N2N3 that closes the conformation of 
the MSCRAMM by covering the trench and interacting with the target sequence. 
D588 appears to interact with Q563 in the Fg Aα chain.  
When the lock regions of SdrE1 and SdrE2 are aligned, there is a 
significantly higher frequency of variations within the Lock domain than within 
the two allelic variants overall (Figure 5-7). A hypothesis was formulated that 
replacing the SdrE2-Lock region with the SdrE1-Lock region would partially 
change the phenotype (as measured in ELISA-type assay) of SdrE2-N2N3 to that 
of SdrE1-N2N3. The SdrE2-LockChimera construct was made by using the 
Overlap Extension PCR technique and then expressed, purified and screened in 
ELISA-type assay for its ability to bind to microtiter wells coated with fibrinogen 





Figure 5-7. SdrE Lock-Latch region alignment. 
 
 
SdrE2-LockChimera is constituted of 97% SdrE2 residues and 3% SdrE1 
residues and is detected in this assay with primary antibody specific to SdrE2-
N2N3. Despite this, SdrE2-LockChimera shows a binding profile more similar to 
the lower affinity, broad specificity binding of SdrE1-N2N3 than SdrE2-N2N3 
(Figure 5-8). The affinity for human fibrinogen appears to be reduced with a 2-5 
fold change in apparent KD when comparing the SdrE2-N2N3 and SdrE-
LockChimera. However, the chimeric mutant still appears to have a greater 




Figure 5-8. SdrE2-Lock Chimera binds fibrinogen from animals. 
 
 
The apparent reduction in affinity was tested in ITC using the human 
fibrinogen peptide mentioned previously (FgAα561-575). SdrE2-LockChimera 
showed a KD = 0.86 μM, a 3.5-fold reduction in affinity for this peptide when 
compared to SdrE2-N2N3. However, when compared to SdrE1-N2N3, the 
SdrE2-Lock Chimera still has a 5-fold stronger affinity (Figure 5-9). This 
suggests that while the lock region plays a very important role in binding, there 
are other residues that contribute to the difference in binding profile between 
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The ability of SdrE2-LockChimera to bind to chips coated with fibrinogen 
from multiple species was tested in SPR experiments by Xiaowen Liang (Figure 
5-10). SPR data confirmed observations from ELISA-type assay and ITC 
regarding SdrE2-LockChimera binding to human fibrinogen with an affinity 
between that of SdrE1-N2N3 and SdrE2-N2N3. Additionally, the SPR data 
confirms the ability for SdrE2-LockChimera to bind fibrinogen from multiple 
species. The ability of SdrE2-LockChimera to interact with dog, cat, and pig 
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fibrinogen shows that the Lock region of these two allelic variants is 
predominantly, but not entirely, responsible for the difference in specificity that 
the N2N3 constructs of these variants display (Figure 5-11). 
 
Structures of apo-SdrE1-N2N3 and SdrE1-N2N3-Fg peptide co-crystal 
Recently, the crystal structures of apo-SdrE1-N2N3 and SdrE1-N2N3-Fg 
peptide co-crystal have been solved by Ganesh Vannakambadi (Figure 5-12). The 
structures are highly similar to that of apo-SdrE2-N2N3 and the SdrE2-N2N3-
Fg Peptide, respectively. These data confirm that SdrE1-N2N3 binds the Fg 
peptide via the Dock, Lock and Latch model. Moreover, the ligand binds to 
SdrE1 through an anti-parallel β-sheet interaction in the ligand binding trench. 
Key differences were discovered in the interaction of the allelic variants with the 
Fg peptide; these differences putatively explain the difference in binding profile 
between the two allelic variants. 
The SdrE2-N2N3-Fg Peptide co-crystal reveals that Fg Aα 561-572 
represent the true binding site with residues 573-575 (Arg-Gly-Asp) being 
outside of the ligand binding trench. Furthermore, 6-7 hydrogen bond 
formations between the backbones of the peptide and MSCRAMM. In contrast, 
in the SdrE1-N2N3-Fg Peptide co-crystal, the true binding site only contains Fg 





Figure 5-10. SPR measurement of SdrE2-LockChimera binding 
coated fibrinogen from various species.  
SdrE2-LockChimera (orange) was tested in the same kinetic experiments as SdrE1-








Furthermore, only 4-5 hydrogen bonds are formed between the peptide 
and MSCRAMM backbones. The reduced number of interacting residues are 
predicted to account for part of the reduction in affinity seen between SdrE1-
N2N3 and human fibrinogen as compared to SdrE2-N2N3. This will be 
confirmed at a later date with experiments using a peptide that represents this 





Figure 5-12. Structure of SdrE1-N2N3-Fg Co-crystal.  
Panel 1 shows the structure of SdrE1-N2N3 bound to the human fibrinogen peptide. The 
N2 domain (green), N3 domain (yellow), fibrinogen peptide (purple), and Latch (red) 
domains are shown. Panel 2 shows an overlay of the fibrinogen-bound structures of 







Mutational analysis of SdrE1-N2N3 
In order to confirm that the residues isolated for their putative role in the 
binding of SdrE1-N2N3 to fibrinogen play an important role, point mutations 
will be made in SdrE1-N2N3. SdrE1-D334A and SdrE1-D558A constructs will be 
made using site directed mutagenesis as described previously. After expression 
and purification, these mutants will be tested for binding to fibrinogen in ELISA-
type assay. The hypothesis is that neither mutant will be able to bind to 
fibrinogen. 
 
Progress towards a chimeric SdrE1 with the binding profile of SdrE2 
Significant progress has been made towards understanding which 
residues of SdrE1 are needed in SdrE2 to change the binding profile to more 
closely resemble SdrE1. Namely, the replacement of the Lock region of SdrE2 
with the SdrE1-Lock region results in an SdrE2-LockChimera that binds human 
fibrinogen with lower affinity and is able to show reduced binding to fibrinogen 
from multiple species. However, attempts at making a chimeric SdrE1-N2N3 
that has the binding profile of SdrE2-N2N3 have been unsuccessful. The Lock 
region of SdrE1 was replaced with the SdrE2-Lock region, but the resulting 
SdrE1-LockChimera showed a reduced affinity for human fibrinogen instead of 
increased affinity and still bound to fibrinogen from multiple other species 




Figure 5-13. SdrE1-LockChimera animal fibrinogen binding profile. 
 
 
Data generated from the solved structures of apo-SdrE1-N2N3 and SdrE1-
N2N3-Fg Peptide co-crystal allows for a greater understanding of the structural 
basis for the differences in binding. Based on these analyses, there are three 
residues that could together be responsible for the differences in binding. In the 
binding of SdrE2-N2N3 to human fibrinogen, SdrE2-Y475 interacts with the 
peptide backbone at FgAα-S570. In SdrE1, this residue is an alanine, which 
prevents this hydrogen bond from forming. Instead, SdrE1-Q467 forms the 
requisite hydrogen bond, but the change in residue results in a shift of the rest of 
the ligand peptide within the ligand binding trench, preventing further contacts 























mutations in the SdrE1-N2N3 construct, this combination mutant should be able 
to have a greater number of contact points than the wild type. Additionally, a 
F582T mutation will allow for additional hydrogen bond interaction with the Fg 
peptide. In sum, it is hypothesized that an SdrE1-Chimera will be made that 
shows a fibrinogen binding profile that closely resembles SdrE2-N2N3.  
 
DISCUSSION 
Previously, we showed that the ligand binding domains allelic variants 
SdrE1 and SdrE2 have dramatically different fibrinogen binding profiles despite 
being highly similar. There are multiple approaches that could have been used to 
find the underlying structural basis for the observed biochemical phenotypes. 
While these variants are 67% identical by amino acid sequence in the ligand 
binding domains, a library of chimeric point mutants would need to contain over 
100 separate mutations from SdrE1 to SdrE2 and another 100 mutations from 
SdrE2 to SdrE1.  
Furthermore, it was likely that we would need to combine multiple 
mutations in order to create a chimeric SdrE1 or SdrE2 that displayed the 
phenotype of the other variant. Instead, we have used the solved crystal 
structures of the ligand binding domains of SdrE1 and SdrE2, in complex with 
their target sequence in fibrinogen, to understand the structural basis of the 
functional differences in binding between SdrE1 and SdrE2. While difficult to 
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obtain, the work by Dr. Ganesh Vannakambadi to solve these structures have 
allowed for a much greater understanding of the mechanism by which these 
SdrE variants binds fibrinogen and identifying the putative residues that are 
critical for binding. The highly similar amino acid sequences of the allelic 
variants resulted in structures that had many similarities; however, upon closer 
inspection, key differences were observed. 
Mutational analysis of the target site in fibrinogen has shown that the 
valine insertion at position 565 significantly reduces the binding capacity of 
SdrE2-N2N3. While the insertion shifts the remaining residues one position, our 
work shows that much of the reduction in binding is caused by the placement of 
the hydrophobic valine in the position where the hydrophilic threonine is located 
in the interaction with human fibrinogen. Additionally, a smaller reduction in 
binding occurs because of the placement of a glycine where an arginine normally 
occurs. These findings strongly suggest that if a mutation by the human host 
were to occur in this region, SdrE2 would more likely to be effected than SdrE1 
due to the high specificity of SdrE2 for the wild type sequence.  
Mutational analysis was used to confirm that residues predicted to play a 
role in binding by the solved crystal structure are critical for binding in vitro. 
These studies allowed for the eventual discovery of a chimeric SdrE2-N2N3 
construct that displayed an intermediate fibrinogen binding profile when 
compared to the binding profiles of the two allelic variants. This construct was 
made replacing the Lock region of SdrE2 with the Lock region of SdrE1. The 
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SdrE2-LockChimera displayed a reduced affinity for human fibrinogen and a 
broad specificity for fibrinogen from non-human species in both ELISA-type 
assay and SPR experiments. While the SdrE1-LockChimera did not result in a 
similar intermediate phenotype, the recently solved SdrE2-N2N3-Fg Peptide 
structure has provided a handful of putative residues that could allow for further 
mutations to be made to create a functionally chimeric SdrE2.  
It is important to note that a small number of changes in amino acid 
sequence result in a large change in phenotype. The fact that SdrE2-N2N3 
displays a markedly higher affinity and specificity for human fibrinogen and the 
fact that there are less variations of sdrE2 in the public database suggest that 
SdrE2 could be an example of host adaptation by S. aureus. While S. aureus is 
mainly a human pathogen, understanding how the bacteria can adapt to other 
hosts has been of significant interest in the field. 
Specifically, mutations in SdrE2 resulted greater binding to human 
fibrinogen; this improvement in function would likely have come at the cost of 
binding to fibrinogen from most animals. There are more changes in amino acid 
sequence between SdrE1 and SdrE2 than are necessary for this change in 
phenotype, but this also speaks to the high frequency of mutation in this region. 
This high frequency of mutation could pose a health risk to humans in light of 
the minimal number of changes necessary for a change in phenotype. It is 
apparent that close monitoring of these regions of Staphylococcus aureus is 
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needed in order to monitor for the emergence of new, highly virulent allelic 
variants. 
Whole genome sequencing is a powerful tool that potentially allows for a 
greater understanding of the evolutionary changes that are occurring within S. 
aureus. However, in silico analysis still needs to be paired with in vitro and in 
vivo research in order to fully maximize the potential of these data. The gain or 
loss of genes and the introduction of stop codons can be detected through 
sequence analysis; however, other variations may be functionally relevant yet not 
readily apparent.  
Allelic variants SdrE1 and SdrE2 provide an example of the latter. With 
the information gained about residues critical for binding in these studies, 
variations in sequence of sdrE can be modeled to project which sequence 





BBP/SDRE2 AND BONE SIALOPROTEIN BINDING 
 
INTRODUCTION 
Osteomyelitis and Staphylococcus aureus 
Osteomyelitis is an infection of the bone that can be caused by bacteria or 
fungi and occurs in approximately 2 out of every 10,000 people. It is generally 
classified by duration, pathogenesis, site, extent and/or type of patient. Mixed 
infections occur frequently enough that osteomyelitis infections are not classified 
by pathogen.8 
There are three major routes of infection for osteomyelitis: primary direct 
infection via trauma or invasive medical procedure, secondary infection via the 
bloodstream, or secondary infection via spread from local tissue infection. The 
most common route of infection depends on the age and comorbidities of the 
patient. In children, hematogenous osteomyelitis is the most common route of 
infection and the long bones are the most common site of infection. It is 
hypothesized that the growing bones of children are more porous to bacteria 
from the vasculature than mature bones in adults.65 Hematogenous 
osteomyelitis can occur in adults, but more often results in an infection of the 
vertebra. In adults, primary direct infection and secondary infection via spread 
from local soft tissue infection are more common than secondary hematogenous 
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osteomyelitis. Primary osteomyelitis is a concern in trauma and surgical 
procedures, especially when implants are placed into the bone tissue. Secondary 
osteomyelitis from local tissue is of particular concern in chronic diabetic 
patients due to the impaired neurovasculature in the distal extremities resulting 
in poor blood flow and reduced sensation. Chronic granulomatous disease and 
sickle cell anemia are also risk factors for osteomyelitis. 9,65 
While mixed infections are common in osteomyelitis, Staphylococcus 
aureus is the leading cause of osteomyelitis across all age groups and 
comorbidities. Approximately 50-70% of osteomyelitis infections contain S. 
aureus. The rise of methicillin-resistant S. aureus has been cited as the biggest 
epidemiologic challenge in osteomyelitis and osteoarticular infections.8 
 
Bbp 
In 1989, it was published by Rydén et al that S. aureus isolates from 
osteomyelitis patients are able to bind bone sialoprotein (BSP).52,66 Further work 
by these investigators isolated an MSCRAMM as the surface factor responsible 
for this binding. This MSCRAMM was named Bone sialoprotein–Binding 
Protein, Bbp.53 The interaction between Bbp and BSP was further isolated to the 
nonapeptide sequence, LKRFPVQGG, that occurs in the N-terminal half of 
BSP.46 Additional evidence for the role of Bbp in staphylococcal osteomyelitis is 
seen in molecular epidemiological studies that show bbp to be overrepresented 
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in osteomyelitis strains compared to staphylococcal strains from all 
pathologies.54 An interesting study has shown a proof of concept for a technique 
that allows for discrimination between SSTI and osteomyelitis in diabetic foot 
infections. The often difficult task is accomplished via serological assay that 
probes for patient antibodies to Bbp. 67 
 
Bone sialoprotein  
Bone sialoprotein (BSP) is a 301 amino acid, highly flexible, extracellular 
matrix protein that is expressed by osteoblasts in bone tissue. Bone tissue is 
made up of two integral components – collagen, which provides elasticity and 
flexibility – and hydroxyapatite mineralization, which provide strength and 
rigidity. While collagen is by far the predominant protein in bone tissue, bone 
sialoprotein is one of the major non-collagen proteins.68 Bone sialoprotein serves 
two major roles in bone tissue. First, it acts as a site of nucleation of 
hydroxyapatite crystal formation. Second, it allows for tissue specific cells to 
attach to the matrix.69 
BSP has been extensively studied and reported on in the literature. BSP is 
divided into 3 sub-regions: a basic N-terminal region, a central domain, and an 
acidic C-terminal region. Within the second half of the central domain, there are 
a number of serine residues that are phosphorylated after BSP is secreted by 
osteoblasts into the bone matrix. The high density of charged phosphate 
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molecules in a concentrated region has been shown to serve as a nucleation site 
of hydroxyapatite crystal formation.68 While other phosphoproteins function in 
hydroxyapatite nucleation, BSP is the most potent known nucleator of 
hydroxyapatite.69 It has recently been discovered that phosphorylation of Ser136 
is critical for the nucleation event.70 The degree of mineralization of bone tissue 
can be regulated by the host via expression of extracellular kinases or 
phosphatases.  
Given that hydroxyapatite has no binding sites for the cells of the bone 
tissue, the ability to bind bone sialoprotein allows these bone cells to bind 
regions of the tissue that are highly mineralized. This interaction occurs through 
a C-terminal RGD motif, a classical integrin-binding motif, as well as sulfated 
tyrosine residues. In addition to these structure-function motifs, there is large 
number of serine, threonine and tyrosine residues, which allow for extensive O-
linked glycosylation, and asparagine residues, which allow for N-linked 
glycosylation.  
Bone sialoprotein plays an important role in the generation of new bone 
tissue. In light of this, it is not surprising that the Bsp gene has been found to be 
upregulated in multiple different mouse models of bone fracture, ranging from 
non-displaced fractures to compound fractures. The expression of Bsp is 
upregulated 3-7 days after injury; this which could play a role as an important 
virulence mechanism for osteomyelitis-causing bacteria.71 In adults, 
Staphylococcus aureus causes osteomyelitis in trauma cases where there is a 
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direct infection of the bone tissue. Given that S. aureus is an opportunistic 
pathogen, the ability to target a host protein that is highly upregulated in trauma 
would be of great benefit to the bacteria. 
 
Conflict in the literature 
Since the publication of SdrE2 binding BSP, the Höök lab has made 
multiple attempts at replicating these findings, but has been unsuccessful. The 
recent publication showing that SdrE2 binds human fibrinogen creates 
conflicting mechanisms of virulence function of SdrE2. The original publications 
found a specific interaction of SdrE2 with bone sialoprotein and no interaction 
with fibrinogen, amongst other ECM proteins.53 Our more recent findings show 
that SdrE2 does bind to fibrinogen, but have been previously unsuccessful at 
showing an interaction with BSP. 47 
 
RESULTS 
Peptide analysis of putative target site of SdrE2 on bone sialoprotein  
Given that previous attempts to show binding between SdrE2-N2N3 and 
full length bone sialoprotein were unsuccessful, we attempted to determine a 
structural-based rationale for binding or lack of binding to BSP using peptides 
representing the published binding sites of human fibrinogen, bone sialoprotein 
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or chimeras of the two. The nonapeptide sequence that Bbp/SdrE2 was reported 
to target in BSP (LKRFPVQGG) bore some similarity to the targeted sequence in 
fibrinogen, especially when comparing the first four residues.46 It was 
determined that the first four residues of the BSP sequence were the most 
important for binding. This is interesting in light of the similarity between the 
first four residues of the human fibrinogen target sequence and the bone 
sialoprotein target sequence. 
Furthermore, when this sequence was queried in the public database, it 
was discovered that the amino acid sequence in this region of BSP is actually is 
LKRFPVQGSSDSS. This contains a single amino acid change from the reported 
sequence. Additionally, we observed that the four residues that occur after the 
reported nonapeptide sequence result in a peptide sequence that is more similar 





Figure 6-1. Attempts at BSP peptide inhibition of SdrE-Fibrinogen.  
Top panel shows alignment of BSP and Fg target sites. Bottom panel shows results of 
Peptide Inhibition ELISA-type assays wherein the published peptide cannot inhibit 




Peptide Inhibition ELISA-type assays were performed in which 0.3 μM 
SdrE1 or SdrE2 was incubated with increasing amounts of the designated 
peptide before this mixture was added to fibrinogen-coated wells. If the protein 
binds the peptide, there is a resultant reduction in signal due to an inability for 
the peptide-bound MSCRAMM to subsequently bind to the fibrinogen-coated 
wells. 
While the Fg peptide was able to inhibit binding of SdrE1-N2N3 or 
SdrE2-N2N3 to fibrinogen-coated wells, the BSP peptide was unable to do the 
same in the initial assay measuring up to a 1:50 ratio of MSCRAMM:Peptide (15 
μM) (Figure 6-2). The experiment was repeated with a concentrations reaching 
an upper limit of 1:1000 (300 μM); SdrE2-N2N3 showed no affinity for this 
peptide. SdrE1-N2N3 showed some interaction, but the concentrations required 







Figure 6-2. Attempts at BSP peptide inhibition of SdrE-Fibrinogen. 
Results of Peptide Inhibition ELISA-type assays wherein the published peptide can not 











Interestingly, a chimeric peptide made of the first four residues of BSP 
and the last 9 residues of Fg is not only bound by SdrE2-N2N3 (Figure 6-3), but 
is bound with an apparent affinity that is even greater than the apparent affinity 
for the wild type Fg peptide. This peptide was made based on the finding that the 
first four BSP residues were critical to binding and also our observation that 
these residues are similar to the first four residues of the Fg peptide.  
The resulting peptide has only two changes from the Fg peptide. These 
findings were confirmed using ITC with the chimeric peptide and SdrE2-N2N3. 
In these experiments, there was a dramatic increase in affinity when compared 
to the wild type fibrinogen peptide (Figure 6-4). We were surprised to note that 
SdrE2-N2N3 displayed a 10-fold greater affinity for this chimeric peptide than it 
did for the wild type human fibrinogen peptide despite the minimal changes. 
This raises the possibility that the binding interactions gained in the first four 
residues could overcome other problematic interactions in the C-terminal half of 





Figure 6-4. ITC measurement of SdrE2-N2N3 binding WT and 
Chimeric Peptide.  
Panel 1 shows the binding curve of the wild type human fibrinogen peptide injected into 







Previously, mutational analysis of the Fg peptide showed that certain 
residues are of critical importance in binding to SdrE2. In this case, we had 
evidence that it was possible to improve the binding interaction between SdrE 
and its ligand, but we had yet to understand the structural basis. To accomplish 
this, chimeric peptides were ordered that contained the changes as noted in 
Table 6-1. These peptides were then tested in Peptide Inhibition ELISA-type 
assays as described previously (Figure 6-5).  
In addition to lack of binding to the BSP wild type sequence, SdrE2-N2N3 
showed no binding to a P->T point mutant or P->T, S->R double mutant. These 
mutations were made because they were shown to affect binding when altered in 
the Fg sequence. Despite the importance of these residues in Fg binding, they 
were not enough to create an interaction with SdrE2-N2N3. While the S->L 
point mutant resulted in a lesser apparent affinity than the wild type Fg peptide, 





Table 6-1. Bone Sialoprotein - Fibrinogen Chimeric Peptides 
 
 





Interestingly, this data corroborates previous experiments from the 
mutational analysis of SdrE2-N2N3 which showed that the D588 residue, 
located in the Lock-Latch region, is critical for SdrE binding. The SdrE2-D588A 
mutant showed no binding to fibrinogen. The solved SdrE2-N2N3-Fg Peptide 
structure provides a subatomic view of the ligand binding trench and the 
interactions with the peptide side chains and backbone. SdrE-D588 interacts 
with FgAα-Q563. By creating the FgAα-Q563R mutation, the negatively charged 
SdrE-D588 is putatively able to form a stronger bond with the positively charged 
arginine as opposed to the hydrogen bond it formed with the glutamine (Fig 6-
5).  
 
Lock variation in SdrE2-Rydén  
In 2000, the Rydén lab published the sequence of the sdrE2 that they had 
been using in their experiments. This sequence matches the sequence of the 
sdrE2 used in the Höök lab, except for one 14 amino acid region (Figure 6-6). At 
the time, this region was not known to be important for binding other than being 
known to be located at the end of the A domain. However, this 14 amino acid 
mutation occurs in the Lock-Latch domain that our structure-function data now 





Figure 6-6. Lock-Latch Region Alignment of SdrE2 
 
 
We have not observed this mutation in other SdrE sequences from 
publicly available databases or collaborators who work in the field of S. aureus 
genomics.  This could mean that the variation observed by the Rydén lab is a 
cloning error or a sequencing error. However, this sequence comes from an 
osteomyelitis strain taken from a patient. It is possible that this isolate acquired 
a mutation that allowed for additional or altered functionality.  
We hypothesized that, since the sequence of the SdrE2 that they use was 
derived from a staphylococcal osteomyelitis strain, they had discovered a variant 
of SdrE2 that does bind to BSP while the more commonly found SdrE2 that is 
used in the Höök Lab does not. To test this hypothesis, an SdrE2-Rydén-N2N3 
construct was made by using a modified Overlap Extension PCR technique (see 
Chapter 2 - Methods).  
SdrE2-Rydén-N2N3 and SdrE2-N2N3 were purified according to 
protocols previously described and then subsequently tested in ELISA-type 
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assays as previously described. In these assays, we were able to acquire bone 
sialoprotein that was purified from a CHO cell line from R&D Systems.   
Surprisingly, wild type SdrE2-N2N3 is shown to bind to bone sialoprotein 
in the ELISA-type assays (Figure 6-7). This had yet to be demonstrated by the 
Höök lab; however, it is possible that this is able to be seen now because the BSP 
used here is derived from a human cell line which ostensibly results in a product 
that contains the many and varied types of glycosylation that bone sialoprotein 
has been shown to have in vivo. It is possible that these post-translational 
modifications play a direct role in binding of SdrE2 to BSP or result in an altered 
folded state of BSP that indirectly affects SdrE2 binding. Glycosylation has been 
shown to affect folding with many other proteins due to the ability of the sugar 
moieties to interact with the surrounding aqueous environment. Bone 
sialoprotein is a heavily glycosylated protein and these glycosylations are 







Figure 6-7. Bone Sialoprotein binding.  
In panel 1, Wild Type SdrE2-N2N3 shows strong binding to Fg and some interaction 




Secondly, it appears as though SdrE2-Rydén binds not only to human 
fibrinogen, but BSP with a very high affinity. However, SdrE2-Rydén also 
appears to interact quite strongly with Mouse Fg, which was meant to serve as a 
negative control for this experiment. This finding raised concerns that the 
changes in SdrE2-Rydén resulted in a large degree of non-specific binding. In an 
attempt to address this, Peptide Inhibition ELISA-type assays were performed in 
order to see if binding by SdrE2-Rydén could be competitively inhibited, which 
would suggest a specific interaction (Figure 6-8).  
Neither form of binding was inhibited, which raises the concern that the 
original observation in ELISA-type assay is could be attributed to non-specific 
binding. Additional concern comes from the knowledge that differences in 
sequence that have been introduced result in a much more hydrophobic set of 
residues in the Lock domain. This domain is supposed to be a flexible, 
hydrophilic domain that interacts with the aqueous environment before 
inserting into the N2 domain. The change to the more hydrophobic sequence of 
SdrE2-Rydén could have unintended consequences on the construct, potentially 







Figure 6-8. Attempts at Peptide Inhibition of SdrE2-Rydén.  
Panel 1 shows lack of peptide inhibition of SdrE2-Rydén binding to fibrinogen while 




SdrE2-Rydén forms putative dimers and multimers which display 
nonspecific binding 
In subsequent purifications of the SdrE2-Rydén-N2N3 construct, we 
observed that peak fractions contained bands of a much higher molecular weight 
in 8% SDS-PAGE gels stained with Coomassie Blue (Figure 6-9). The predicted 
size of SdrE2-N2N3 is 34 kDa, which has been confirmed by mass spectrometry. 
In SDS-PAGE, SdrE2-N2N3 migrates between the 56 kDA and 45 kDA markers. 
SdrE2-Rydén-N2N3, being a mutant that has exchanged residues in the lock and 
latch region, has the same number of amino acids as well as the same predicted 
size. However, there was an observed band at approximately 80 kDa and another 




Figure 6-9. SDS-PAGE/Coomassie.  
Panel 1 is a purification gel of SdrE2-N2N3. Panel 2 is a purification gel of  SdrE-Rydén 




There are no cysteine residues in the SdrE2-Rydén-N2N3 amino acid 
sequence which excludes the possibility that any putative dimerization or 
multimerization is occurring through disulfide bond formation. This was 
confirmed through running reducing and non-reducing gels (data not shown), 
which showed no difference in banding pattern. To further investigate the size 
and nature of these putative multimers, purified SdrE2-Rydén-N2N3 samples 
were purified through size exclusion chromatography using a 120 mL Sephacryl 
S-200 gel filtration column.  
The SEC data confirmed that in addition to a monomer of approximately 
34 kDa, SdrE2-Rydén-N2N3 also dimerizes and multimerizes (Figure 6-10). The 
largest peak occurs in the void volume of the column, consistent with a multimer 
of an indeterminate size.  The putative dimer peak occurs at 75 kDa. Running the 
samples of a reducing SDS-PAGE gel showed the presence of a band that 
migrated at the size of the monomer, but this is likely an effect of the gel 
conditions. Importantly, the presence of a high molecular weight species 
representing the putative multimer and an 80 kDa molecular weight species 
representing the putative dimer are very faint in the fractions from the monomer 




Figure 6-10. Size Exclusion Chromatography of SdrE2-Rydén. 
The three peaks in SEC correlate to 3 bands on SDS-PAGE. 1: SdrE2-Rydén Multimer, 
2: SdrE2-Rydén Dimer, 3: SdrE2-Rydén Monomer. 
 
 
Given that this multimerization was occurring without disulfide bonds, it 
was hypothesized that the multimerization process may be a reversible process 
that could be driven towards the monomeric state via dilution. To test this, the 
multimer and dimer fractions were diluted 10-fold using 1x TBS buffer, and then 
slowly concentrated to 5 mL to run a second time on SEC on the 120 mL 




Figure 6-11. SdrE-Rydén SEC Repeat.  
Panels 1 and 2 show the individual runs of the (1) multimer and (2) dimer peaks. As 
seen in the overlay (3) of these two runs with the original run, there is no change in the 
distribution from the (1) multimer peak fractions or (2) dimer peak fractions. 
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Upon a second SEC run after dilution and slow concentration, the data 
show that there was no change in the rate at which the multimer fractions or 
dimer fractions migrated through the column (Figure 6-11). While this does not 
disprove the hypothesis that the multimerization is a reversible event, it does 
suggest that any reversion to the monomeric state is likely to occur very slowly 
without the aid of secondary agents. However, it is useful to know that the 
monomer, dimer and multimer remained in their respective states because it 
allowed for further experimentation to determine if this multimerization results 
in a change in binding phenotype. To test for a change in phenotype, ELISA-type 
assays were used in which microtiter wells were coated with human fibrinogen, 
bone sialoprotein or mouse fibrinogen. 
The multimerization state of SdrE2-Rydén-N2N3 affected the binding 
profile to human fibrinogen, bone sialoprotein and the negative control, pig 
fibrinogen (Figure 6-12).  SdrE2-N2N3 only showed an affinity for human 
fibrinogen at these concentrations. Monomeric SdrE2-Rydén-N2N3 showed the 
greatest affinity for human fibrinogen also, but also displayed the ability to bind 
bone sialoprotein and pig fibrinogen. The dimeric form showed an equal affinity 
for all three ligands while the multimeric form is notable for the apparent loss of 
affinity for bone sialoprotein. The apparent interaction with pig fibrinogen by 






Figure 6-12. Fibrinogen and Bone Sialoprotein binding by SdrE-
Rydén.  
ELISA-type assays show different binding profiles for (1) wild type SdrE-N2N3, (2) 







Peptide Inhibition ELISA-type assays were performed to confirm that 
SdrE2-Rydén-N2N3 interacts with human fibrinogen at the previously described 
target site and to test for binding of the BSP peptide or the BSP/Fg chimeric 
peptides (Figure 6-13). The lack of BSP binding in ELISA-type assay and the 
difficulty in measuring or estimating the number of SdrE2-Rydén-N2N3 
molecules in each multimer lead us to focus on the monomeric and dimeric 









The monomeric and dimeric forms of SdrE2-Rydén-N2N3 showed a 
significantly different peptide inhibition profile than that of SdrE2-N2N3. 
SdrE2-N2N3 shows a strong affinity for the wild type fibrinogen peptide and the 
BSP/Fg chimeric peptide in which the first four peptides are from BSP (Figure 6-
14). This dose-dependent affinity results in 90% inhibition at a 1:100 ratio of 
MSCRAMM:Peptide (50μM). It shows no affinity for the BSP peptides that 
contain point mutations to the Fg sequence.  
In contrast to SdrE, the monomeric SdrE2-Rydén-N2N3 shows 60% 
inhibition by all of the peptides at very low concentrations, which suggests a very 
high affinity for each of them. However, none of the peptides are able to achieve 
the 90% maximum inhibition as is seen with SdrE2-N2N3 (Figure 6-15). This is 
an unexpected finding because peptides that show 50% inhibition of 
MSCRAMMs binding their respective ligands in Peptide-inhibition ELISA-type 
assays at low concentrations are almost always able to fully inhibit the 






Figure 6-14. Peptide Inhibition of SdrE2-Rydén Monomer. 
Panel 1 shows inhibition of SdrE2-Rydén monomer binding to fibrinogen. Panel 2 




Interestingly, the BSP peptide shows the best inhibition of monomeric 
SdrE2-Rydén-N2N3 binding to bone sialoprotein. These four peptides show a 
20-40% inhibition of dimeric SdrE2-Rydén-N2N3 binding to human fibrinogen, 
but only one peptide shows a similar ability to inhibit binding to bone 
sialoprotein. This chimeric peptide is derived from the BSP peptide and contains 
two point mutations where the residues are changed to human fibrinogen. Given 
the lower levels of inhibition seen with the dimer as compared to the monomer, 
it appears that dimerization has affected the specificity of binding of SdrE2-
Rydén-N2N3.  
Attempts were made to study the interaction of the monomeric SdrE2-
Rydén-N2N3 with the human Fg peptide, BSP petide and BSP/Fg chimera 
peptide in isothermal titration calorimetry experiments. However, no clear 
results were seen due to lack of consistently measurable heat given off during the 





Figure 6-15. Peptide Inhibition of SdrE2-Rydén Dimer.  
Panel 1 shows inhibition of SdrE2-Rydén dimer binding to fibrinogen. Panel 2 shows 





Bbp/SdrE2 was originally named for its ability to bind to bone 
sialoprotein; however, whether the most commonly found version of SdrE2 is 
actually capable of binding BSP with high affinity remains to be proven. If 
Bbp/SdrE2 is unable to bind bone sialoprotein, then recent findings of is ability 
to bind to fibrinogen with high affinity and it being an allelic variant of SdrE1 
strongly suggest that a change in nomenclature is in order. A change in 
nomenclature to SdrE2 would allow for greater clarity in the field when 
reporting the incidence, frequency and variations within these allelic variants.  
Mutational analysis of the reported target sequence within BSP suggests 
that the first four residues, previously determined to be important for binding, 
are able to interact with SdrE2-N2N3. This indicates that the lack of binding to 
the reported BSP target sequence is due to one or multiple differences in the 
subsequent residues in the sequence. 
The report of the SdrE2-Rydén sequence in 2000 raised the possibility 
that the previously published data regarding BSP binding involved an SdrE2 
variant from an osteomyelitis isolate that had accumulated a significant number 
of mutations in the Lock-Latch region, shown above (Chapter 4) to be critical for 
binding. The SdrE2-Rydén-N2N3 construct was made through Overlap 
Extension PCR of the SdrE2-N2N3 construct and was then tested in ELISA-type 
assay and Peptide Inhibition ELISA-type assay.  
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The changes in sequence resulted in the generation of dimers and 
multimers during the expression and purification process. These multimers 
displayed a different binding profile from the monomer and had to be purified 
via size exclusion chromatography. We hypothesize that this is occurring because 
the introduction of a large number of hydrophobic residues to a region that is 
normally flexible, hydrophilic and exposed to the surrounding environment 
results. Multimerization may be induced by the hydrophobic effect where these 
residues are buried to prevent interaction with aqueous solvents.   
It is unclear at this time whether SdrE2-Rydén-N2N3 represents a true 
virulence factor with a bone sialoprotein-binding mechanism of virulence or 
some form of error in cloning or sequencing. It should be noted that the 
nucleotide sequence is the same except for a nucleotide insertion right before the 
Lock region, a frameshift mutation that causes changes in all of the subsequent 
codons until a nucleotide deletion that occurs at the end of the Latch region 
resets the reading frame.  
Interestingly, SdrE2-N2N3 did show an interaction with bone 
sialoprotein in ELISA-type assay, but it appeared to be a minor interaction of 
modest affinity when compared to the affinity of SdrE2-N2N3 for human 
fibrinogen. Future work is expected to confirm that while SdrE2-N2N3 can bone 





SDRE1 BINDS FACTOR H 
 
INTRODUCTION 
Other ligands for SdrE 
The observed frequencies of sdrE1 and sdrE2 in staphylococcal isolates 
gathered from non-human species is significantly different when compared to 
isolates taken from humans. sdrE1 is present in 88% of staphylococcal isolates 
from a survey of animal species, while sdrE2 is found in 11% of these isolates. In 
human disease, sdrE1 is found in 55% and sdrE2 is found in 32% of isolates. 
Interestingly, our lab has shown that the biochemical binding profiles of sdrE1 
and sdrE2 provide a rationale for the observed overrepresentation of sdrE1 in 
animal isolates. The ligand-binding N2N3 domain of SdrE2 shows a high affinity 
for human fibrinogen with a lesser ability to interact with bovine fibrinogen and 
no measurable binding capacity for fibrinogen from other species. In contrast, 
SdrE1-N2N3 shows a lesser affinity for human fibrinogen when compared to 
SdrE2-N2N3, but a more promiscuous binding profile that includes the ability to 
bind to fibrinogen from multiple species. These biochemical data provide a 
functional rationale for the observation that S. aureus colonizing a non-human 




However, when focusing on the gene frequencies of these allelic variants 
in human isolates only, the biochemical binding profiles of SdrE1-N2N3 and 
SdrE2-N2N3 do not adequately provide a rationale for the observed frequencies. 
SdrE2-N2N3 displays a 45-fold higher affinity for human fibrinogen than SdrE1-
N2N3. If fibrinogen was the only host protein targeted by these allelic variants, 
sdrE2 would be expected to be observed at significantly higher frequencies than 
sdrE1. One possible explanation for this observation is that S. aureus moves 
between species with enough frequency that retention of sdrE1 imparts a 
competitive advantage. However, few published studies support host species 
transfer rates at such high levels. 
Another, more likely, possibility is that the targeting of other human 
proteins by SdrE1 confer a competitive advantage. As mentioned previously, 
most MSCRAMMs show the ability to bind to multiple targets. The 
multifunctional capability of MSCRAMMs is important to bacteria that need to 
maintain efficient genomes. Given these previous findings regarding MSCRAMM 
targets, it would be expected that SdrE1 is capable of binding to multiple targets. 
Furthermore, given that sdrE1 occurs at greater frequencies in 
staphylococcal isolates taken from humans than sdrE2, we hypothesize that 
secondary targets of SdrE will be bound with higher affinity by sdrE1 than 
sdrE2. In this model, sdrE1 would provide a competitive advantage to S. aureus 
over sdrE2 by allowing for multiple functionalities while sdrE2 provides a single 




In May, 2012, it was published that SdrE binds to Factor H, a member of 
the alternative complement pathway.45 This group has published previously that 
another MSCRAMM in the Sdr family, ClfA, binds to Factor I, another member 
of the alternative complement pathway.35 The complement system is an integral 
part of the innate immune defense whereby pathogens and foreign bodies are 
targeted and removed via opsonization and localized anaphylactic processes. 
While all three pathways of the complement system result in the generation of 
C3 convertases, in the alternative complement pathway, the C3 convertase 
C3bBb can be activated spontaneously. In order for the host to protect itself from 
non-specific activation and attack by the alternative pathway, soluble secreted 
inhibitors and cell membrane-bound inhibitors of this convertase are produced 
by the host. Factor I plays an inhibitory role in the pathway by enzymatically 
cleaving activated C3b to creat inactive iC3b. Factor H is another inhibitor of the 
alternative complement pathway that has two modes of action.72 One 
mechanism involves initiating the irreversible disassociation of C3b and Bb. The 
second mechanism involves working as a co-factor for the enzymatic cleavage by 






Factor H in human disease 
The importance of the role of Factor H in binding to human cells and 
inhibiting the alternative complement system is seen in a variety of pathologies 
that have been linked to mutations and single nucleotide polymorphisms in the 
Factor H gene. It has recently been reported that 35% of individuals are carriers 
of a Y402H mutation in Factor H; this mutation is correlated to an increased risk 
in age-related macular degeneration.73 Homozygous and heterozygous carriers 
have sevenfold and threefold increased risks for the disease, respectively. 
Additionally, a subset of atypical hemolytic uremic syndrome is strongly linked 
to mutations in Factor H and other regulators of the complement system. Factor 
H mutations or deletions can also result in Membranoproliferative 
Glomerulonephritis type II (MPGN II) due to the resulting increased levels of 
circulating C3 activation products (C3a and C3b).74  
 
Factor H structure 
Factor H is a secreted 155 kDa serum protein. It is composed of 20 repeat 
regions, termed SCRs, and has an overall structure that resembles a beads-on-a-
string appearance. The size and flexibility of Factor H has made crystallization of 
the whole protein difficult to achieve, but smaller portions of the structure have 
been elucidated. Analysis through use of truncation mutations has isolated the 
various functionalities and target domains of Factor H to different sets of SCRs. 
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Factor H is bound to host cells via its C-terminal SCRs, 18-20, which interact 
with the glycosaminoglycans that are attached to the surface of mammalian cells 
but are absent in bacterial and yeast cells. There are multiple sites for the 
binding of heparin and C3b. Recently, it was published that soluble Factor H 
dimerizes and that this dimerization occurs through SCRs 5-7 and 19-20.75  
The potent inhibitory effect of Factor H on the alternative complement 
pathway is exploited by a variety of pathogens to evade the innate immune 
system. Yeast such as Candida albicans, the spirochete Borrellia burgdorferi, 
the Gram-negative Neisseria gonorrhea, and other Gram-positives such as 
Streptococcus pyogenes and Streptococcus pneumonia express proteins that 
bind to Factor H. These pathogens coat themselves with Factor H, resulting in 




SdrE1-N2N3 binds Factor H in a specific manner with maximal 
binding in ELISA-type assay 
In Sharp et al, the ELISA data did not show saturation in the interaction 
of SdrE1 with Factor H, thus making estimations of KD impossible. This raises 
the possibility that the observed binding was a non-specific interaction. If SdrE1 
 147 
 
interacts with Factor H in a non-specific manner or with low affinity, it is 
unlikely to be an effective mechanism of virulence.  
In order to confirm that SdrE1 does bind Factor H, ELISA-type assays 
were performed using Factor H-coated wells and increasing amounts of purified 
recombinant SdrE1-N2N3. While the recombinant SdrE construct in Smith et al 
was composed of the SdrE A domain, the recombinant protein used in these 
experiments is the N2N3 constructs that were used previously to study the 
structure-function relationship of the SdrE-Fibrinogen interaction.  
Also, in contrast to Sharp et al, where microtiter wells were coated with 
recombinant MSCRAMMs and then probed with increasing amounts of Factor 
H, these experiments reverse this process by probing Factor H-coated microtiter 
wells with recombinant MSCRAMMs. This is a more accurate reflection of the 






Figure 7-1. SdrE1-N2N3 binds Factor H, while SdrE2-N2N3 does not.  
Panel 1 shows that SdrE1-N2N3 binds to Factor H to a similar degree as it does to 





Figure 7-1 shows that SdrE1-N2N3 binds to Factor H-coated microtiter 
wells with a similar affinity as SdrE1-N2N3 binds to human fibrinogen-coated 
microtiter wells. SdrE1 shows a promiscuous binding profile, as seen by its 
saturable, dose-dependent interaction with cow fibrinogen in this experiment. 
SdrE1 also binds Factor H strongly with an apparent KD = 1 μM. Furthermore, 
SdrE2-N2N3, previously shown to be a highly specific, high affinity binder of 
human fibrinogen, does not interact with Factor H in these assays. Thus, Factor 
H provides an example of a ligand that satisfies our hypothesis regarding an 
alternate human target for SdrE in that SdrE1-N2N3 binds to it with significantly 
greater affinity than SdrE2-N2N3. Attempts were made to duplicate the Sharp et 
al data by probing MSCRAMM-coated wells with Factor H, however no binding 
was seen. This could be due to differences in affinity of primary anti-fH 
antibody. Alternatively, this could be explained by differences in SdrE affinity for 
Factor H based on whether it is in the soluble, flexible or coated, restrained state.  
 
SPR analysis of SdrE allelic variants binding Factor H 
Due to the size, flexibility and cost of Factor H, ITC experiments were not 
feasible. Furthermore, the inability to show binding via ELISA-type assay or SPR 
of soluble Factor H to bind to coated SdrE1-N2N3 suggests that it would be 
difficult to study this interaction in solution. Instead, SPR experiments were 
performed by Xiaowen Liang that analyzed the binding kinetics of the SdrE 
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allelic variants to immobilized Factor H. As shown in Figure 7-2, SdrE1-N2N3 
binds tightly to Factor H , KD = 0.16 μM. Surprisingly, SPR was also able to show 
an interaction between SdrE2-N2N3 and Factor H, but one with a 23-fold lower 
affinity when compared to SdrE1-N2N3 and Factor H.  
We hypothesized that the differences in affinity for Factor H seen between 
the two SdrE allelic variants were due to the same structural features that were 
shown to be important in fibrinogen binding. To test this hypothesis, SdrE2-
LockChimera was injected over the same Factor H-coated chip as SdrE1-N2N3 
and SdrE2-N2N3 (Figure 7-3). The data show that SdrE2-LockChimera 
displayed a similar high affinity binding of Factor H that SdrE1-N2N3 showed 
(Table 7-1). This helps to confirm the hypothesis that the same structural 
features of SdrE are important for binding both fibrinogen and Factor H. It also 
lends further evidence that the Lock region plays an important role in ligand 






Figure 7-2. SPR measurement of SdrE1-N2N3 and SdrE2-N2N3 
binding Factor H.  
Panel 1 shows the promiscuous binding, SdrE1-N2N3 binding to Factor H in SPR 







Figure 7-3. SdrE2-LockChimera binds Factor H similarly to SdrE1-
N2N3.  





























Progress towards isolating the target site of SdrE on Factor H 
Attempts were made to find the specific target sequence in Factor H 
through two main approaches. First, the site in human fibrinogen that is 
targeted by SdrE1 and SdrE2, a 15mer from the fibrinogen Aα chain, was used to 
query for similar sequences in the Factor H amino acid sequence. The Factor H 
region that had the highest similarity was found to be Factor H 820-832, which 
occurs in SCR 13. Peptide inhibition ELISA-type assays were performed as 
described previously (Figure 7-4). While the human Fg peptide was able to 
inhibit the interaction between the SdrE allelic variants and fibrinogen, the 
Factor H peptide was not able to inhibit in a measurable concentration range. 
In contrast to SdrE, the monomeric SdrE2-Rydén-N2N3 shows 60% 
inhibition by all of the peptides at very low concentrations, which suggests a very 
high affinity for each of them. However, none of the peptides are able to achieve 
the 90% maximum inhibition as is seen with SdrE2-N2N3 (Figure 6-15). 




Figure 7-4. Putative Factor H binding site does not inhibit SdrE – 
Fibrinogen.  
Panel 1 shows the putative Factor H binding site, designed from alignment studies with 
the human fibrinogen  binding site. Panels 2 and 3 show Peptide Inhibition ELISA-type 
assays using these peptides to inhibit the binding of SdrE1-N2N3 and SdrE2-N2N3, 




Figure 7-5. SdrE1 and Bbp/SdrE2 binding to Factor H fragments. 
 
 
Our second approach to discover the binding site in Factor H used 
truncation mutants that were probed with the N2N3 domains of the SdrE allelic 
variants in SPR experiments performed by Xiaowen Liang (Figure 7-5). These 
data show that while Bbp/SdrE2-N2N3 is unable to bind to any fragments, 
SdrE-1 was able to bind to a truncation mutant containing the first ten SCRs. 
The inability of SdrE1-N2N3 to bind to the first 5 SCRs strongly suggests that the 
MSCRAMM is likely targeted to SCRs 5-10. Further experimentation narrows 
this range down to SCRs 5-7 (data not shown). 
 
Compare binding to immob. fH fragments SCR1-5 and SCR1-10




























We have shown previously that the in vitro fibrinogen-binding 
characteristics of allelic variants SdrE1 and SdrE2 provide a rationale for the 
observed differences in gene frequencies between staphylococcal isolates 
gathered from humans and from animals. However, the human fibrinogen-
binding profiles of these variants suggest a significantly different set of allelic 
frequencies should be expected in human staphylococcal isolates than what is 
observed. One hypothesis for this discrepancy is the existence of other host 
ligands provides a countervailing function for SdrE1. A recent publication 
provides evidence that SdrE1 binds Factor H, presenting a putative secondary 
ligand to match our hypothesis. 
Building off of this initial report, we provide additional evidence that 
ligand-binding domain of SdrE1 binds to coated Factor H. While Sharp et al 
show an interaction, here we show data from analytical biochemical techniques 
that not only confirm the interaction, but provide information about the 
parameters of the binding event. Further work with coated Factor H truncation 
mutants will allow for isolation of the specific residues targeted by SdrE. It is 
possible that the binding of Factor H by SdrE1 does not follow the Dock, Lock, 
and Latch model as seen in the SdrE-Fibrinogen interaction. Factor H has a 
“beads on a string” conformation that only displays 4-8 amino acids on the 
“string” in between the SCRs. This makes it difficult to envision SdrE binding to 
a linear 11mer as seen with fibrinogen binding. If SdrE binds via a different 
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mechanism, then the search for a linear peptide of 10-15 amino acids is unlikely 
to yield conclusive results. Factor H truncation mutants representing single SCR 
domains, each approximately 60 amino acids, provides the best experimental 
approach for determining the binding site in this model. Alternatively, it is 
possible that coating of Factor H results in a conformational stretching that 
uncovers a linear sequence that is long enough for SdrE1 to attach via the Dock, 
Lock and Latch model.  
Based on the high affinity displayed by SdrE1 for Factor H in the data 
presented above, we hypothesize that the SdrE1-Factor H interaction observed in 
vitro is important for in vivo virulence. This virulence mechanism is likely due to 
putative ability of Factor H-coated bacteria to inhibit the alternative complement 
pathway. Sharp et al provides evidence that presence of SdrE on the avirulent 
Gram positive bacteria Lactococcus lactis reduces the deposition of C3 
fragments and C5a generation. Further experimentation is needed to confirm 
that full length SdrE1 on the surface of bacteria, specifically S. aureus, results in 
a similar reduction in C3 fragment deposition and complement fragment 
anaphylotoxins, as well as increased virulence in vivo. This could be done with S. 
aureus Newman Bald derivative strain, which has many MSCRAMMs removed, 
allowing for a clearer understanding of the role of SdrE1 in staphylococcal 
virulence. 
It is possible that the higher affinity for Factor H of SdrE1 compared to 
SdrE2 is necessary and sufficient to explain the observed difference in gene 
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frequencies of these allelic variants in staphylococcal isolates taken from 
humans. However, the ability of MSCRAMMs to bind multiple targets suggests 
that the SdrE allelic variants could also target other host proteins. It is not clear 
if the ability of SdrE1 to bind Factor H provides an evolutionary advantage to S. 
aureus that overcomes the benefit of a higher affinity interaction with fibrinogen 
that SdrE2 provides. If there are additional ligands for these allelic variants 
involved, the respective affinities of SdrE1 and SdrE2 for new ligands would be 
difficult to predict based solely on epidemiological evidence. However, the 
biochemical data that we have gathered regarding the highly specific nature of 
SdrE2 binding to human fibrinogen suggests that SdrE2 will have low to no 
affinity for other ligands. The more promiscuous SdrE1would be the variant 
expected to be able to interact with other ligands. 
In silico analysis was used to identify putative ligands for SdrE. A BLAST 
search was performed using the SdrE target sequence in human fibrinogen. A 
sequence from cytokeratin 14 was discovered from this search that is highly 
similar to the fibrinogen sequence (Figure 7-6). The ability of another 
MSCRAMM from the Sdr subfamily, ClfB, to interact with cytokeratin 10 has 
been published previously. This interaction is important for the ability of S. 
aureus to colonize the nares of the human host. SdrE binding of cytokeratin 14 









It is interesting to note that the similarity occurs in the first nine amino acids 
of the human fibrinogen sequence. The solved crystal structure of SdrE1 in 
complex with this peptide shows contact points between these nine amino acids, 
while structural data from the SdrE2-Fibrinogen interaction shows that SdrE2 
interacts with 13 amino acids in fibrinogen. Based on these data, it is predicted 
that if cytokeratin is bound by SdrE, SdrE1 is likely to bind with higher affinity 





CONCLUSION AND FUTURE DIRECTIONS 
 
CONCLUSION 
SdrE/SdrE1 and Bbp/SdrE2 are allelic variants  
SdrE and Bbp have heretofore been regarded by most of the S. aureus 
literature as individual, unrelated members of the Sdr family of staphylococcal 
MSCRAMMs. SdrE is named for its location in the S. aureus core genome as the 
last member of the sdrCDE gene cluster. Bbp was named for its functional 
capacity as a bone sialoprotein binding protein. While there were some reports 
suggesting SdrE played a role in virulence, invasiveness and platelet activation, 
SdrE had no proven function until a recent publication showing that SdrE binds 
to Factor H. 
Our research here shows that these MSCRAMMs are actually allelic 
variants. Bbp and SdrE have highly similar amino acid sequences that show 87% 
sequence identity and 95% sequence similarity within the A domain and B 
repeats. Furthermore, both genes are located in the same position in the S. 
aureus genome at the end of the sdrCDE gene cluster. Additionally, sdrE1 and 
sdrE2 are found together in less than 1% of S. aureus isolates. When they have 
been found in the same isolate, one generally occurs on a mobile genetic 
element. A portion of these double positive isolates are likely false positives that 
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result in counting one of the allelic variants twice due to the difficulty inherent to 
constructing primers for sequences that are so similar. Mapping the amino acid 
sequences of SdrE using dendogram analysis shows two allelic variants that bear 
more similarity to each other than any other MSCRAMM of the Sdr family, yet 
still segregate completely by allele with no crossover or intermediate variant.  
In light of these data, we propose a change in nomenclature to dispel the 
notion that these are separate virulence factors. Given that Bbp/SdrE2 binds 
with high affinity to human fibrinogen and shows little affinity for bone 
sialoprotein, a name that reflects only bone sialoprotein binding is not ideal. In 
light of this and the higher frequency of SdrE, we propose a change in 
nomenclature of these allelic variants from SdrE to SdrE1 and Bbp to SdrE2.  
When sdrE1 and sdrE2 genetic sequences are aligned, the number of 
variations can be looked at for each region of the gene. If sdrE1 and sdrE2 were 
individual virulence factors, it would be expected that the number of variations 
stayed constant across each domain. Instead, the N1 and B1-B3 domains are 
greater than 95% identical, while most of the variations are concentrated within 
the ligand binding N2 and N3 domains. In addition to providing additional 
evidence for the hypothesis that these two MSCRAMMs are actually allelic 
variants, there are a number of interesting applications for this observation. 
First, it is unusual that the domains that are currently predicted to only play a 
role in protrusion and display of the ligand binding domain are highly conserved 
while the functional, ligand binding domains are less conserved. This is the 
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opposite of the expected variation distribution, especially in comparison to 
critical residues in enzymes. It suggests that SdrE provides S. aureus with a 
somewhat redundant function resulting in less evolutionary pressure on the 
bacteria to maintain high fidelity during replication of these regions. The ability 
to allow for mutation in the effector domain of the virulence factor allows S. 
aureus to potentially adapt to its host by developing virulence factors that attach 
to new host proteins or to bind with greater affinity to its original target. Given 
that there are more variations within sdrE1 alleles than sdrE2 alleles, it seems 
likely that sdrE2 came from sdrE1.  
 
SdrE1 and sdrE2 show significantly different distributions amongst 
isolates from humans and animals. 
In S. aureus isolates taken from humans, sdrE1 is found in approximately 
55% of isolates while sdrE2 is found in approximately 32% of isolates. In 
contrast, S. aureus isolates taken from a wide array of animals from multiple 
continents found that sdrE1 is present in 88% of isolates while sdrE2 is present 
in less than 11% of isolates. 75% of the isolates from animals that did contain 
sdrE2 came from bovine species. These findings suggest that the distribution of 
sdrE allelic variants provides an example of S. aureus adaptation to different 
host species.  
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It is known that one mechanism of host adaptation displayed by S. aureus 
that has transitioned hosts from humans to animals is the rapid loss of virulence 
factors that are only functional against human targets. This phenomenon has 
been shown for staphylococcal virulence factors such as clfA and hlaB. The 
observed allelic distribution suggests that sdrE1 and sdrE2 provide another 
example of host adaptation with the loss of sdrE2 in most isolates form animals 
except bovine species.  
 
SdrE1 and SdrE2 display significantly different fibrinogen binding 
profiles 
Our lab recently published that Bbp/SdrE2 binds to human fibrinogen Aα 
chain at residues 561-575.47 Initial screens of the ligand binding N2N3 domain of 
SdrE2 with fibrinogen from other animals showed that SdrE2 displayed a high 
degree of specificity for human fibrinogen. Given the high degree of sequence 
identity between SdrE1 and SdrE2, we hypothesized that SdrE1 would also bind 
to human fibrinogen.  
We show through ELISA-type assays, ITC and SPR experiments that 
SdrE1-N2N3 does bind to fibrinogen, but displays a significantly differently 
binding profile as compared to SdrE2-N2N3. SdrE2-N2N3 shows a 45-fold 
greater affinity for human fibrinogen than SdrE1-N2N3; however, SdrE1-N2N3 
displays the ability to bind to fibrinogen from a broad sampling of species while 
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SdrE2-N2N3 only shows affinity for human fibrinogen and, to a much lesser 
extent, bovine fibrinogen.  
Our molecular epidemiology data on SdrE strongly suggests that SdrE2 
came from SdrE1. When viewed in combination with the biochemical data, it 
appears likely that sdrE2 is an example of adaptation to the human host. The 
accumulated mutations in the N2N3 domain resulted in a significantly greater 
ability to bind to human fibrinogen, but also resulted in a reduced ability to bind 
to animal fibrinogen. Given that S. aureus is still mainly a human pathogen, it’s 
not surprising that sdrE2 is consistently present in these isolates at higher levels 
than what is seen in isolates from animals.  
Interestingly, the fibrinogen binding profiles of SdrE1 and SdrE2 as 
measured in these biochemical experiments correlates strongly to the differences 
in allelic frequencies observed in staphylococcal isolates taken from animals 
compared to humans. SdrE1-N2N3 displays a broad species binding profile and 
the sdrE1 gene is found at a higher frequency in isolates from animals when 
compared to the frequency of sdrE1 in isolates taken from humans. Similarly, 
SdrE2-N2N3 displays little affinity for fibrinogen from most non-human species 
and sdrE2 is found to have a significantly lower gene frequency in isolates taken 
from animals. Additionally, 9 of the 12 isolates that came from animals that were 
shown to contain sdrE1 came from bovine species, while bovine fibrinogen was 




With the growing incidence of Livestock Acquired-Methicillin Resistant 
Staphylococcus aureus (LA-MRSA) infections, there is a need to understand 
how a bacterium like S. aureus that is most often associated with human 
colonization and pathogenesis is able to move between such a large number of 
different species. These findings show that SdrE plays a role in S. aureus species 
adaptation with the presence of sdrE1 generally conferring an advantage to S. 
aureus over sdrE2.  
 
Understanding the structure-function relationship of the SdrE – Fg 
interaction 
The significantly different fibrinogen binding profiles of sdrE1 and sdrE2 
are surprising given the high degree of sequence identity between the two allelic 
variants within their ligand binding domains. In order to understand the 
structural basis for this biochemical observation, we collaborated with a 
crystallographer Dr. Ganesh Vannakambadi. This collaboration resulted in the 
solved crystal structures of SdrE2-N2N3 in an open conformation, as well as 
SdrE2-N2N3 in complex with the fibrinogen peptide representing the target site. 
These data support that SdrE2 binds to fibrinogen via the Dock, Lock and Latch 
mechanism.  
Mutational analysis of the fibrinogen target sequence was performed in 
order to understand how SdrE2 displays a high specificity for human fibrinogen, 
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and to a lesser extent, bovine fibrinogen, given that there are so few differences 
within the corresponding target regions of fibrinogen from other species. Our 
data show that the valine insertion at position 565, which contains a threonine in 
humans, is capable reducing the affinity of SdrE2-N2N3 for this region by over 
100-fold, as measured in Peptide Inhibition ELISA-type Assay with a peptide 
that contains a T565V mutation. Other changes, such as the subsequent R573G 
change, also affect binding, but do so at a much lesser level. As more human 
genome sequences become publicly available, it will be interesting to see if any 
mutations occur within this region and if those mutations result in a greater 
resistance to S. aureus colonization or infection. 
Additionally, mutational analysis was performed to create a chimeric 
SdrE2-N2N3 that would display the binding phenotype of SdrE1-N2N3 while 
changing as few residues as possible. While no single point mutation resulted in 
an SdrE1-N2N3 binding phenotype, it was discovered that replacing the Lock 
domain of SdrE2 with the Lock domain from SdrE1 resulted in a chimeric 
construct did. SdrE2-LockChimera has 10 amino acids from SdrE1 yet displays a 
lower affinity for human fibrinogen and the ability to interact with fibrinogen 
from multiple species in a manner that is more similar to SdrE1 than SdrE2. The 
dramatic impact that such a small region can have on binding suggests that the 
Lock domains in SdrE and other MSCRAMMs should be monitored to watch for 




Factor H provides another human target and a rationale for observed 
allelic frequencies 
The in vitro fibrinogen binding profiles of SdrE1 and SdrE2 provide a 
rationale for the observed differences in allelic distribution between 
staphylococcal isolates gathered from humans and animals.  However, when 
restricting the focus to solely the allelic frequencies in human isolates, the 
binding profiles of SdrE1-N2N3 and SdrE2-N2N3 do not adequately provide a 
rationale for the observed allelic frequencies. SdrE2-N2N3 displays a 45-fold 
higher affinity for human fibrinogen than SdrE1-N2N3. If fibrinogen was the 
only host protein targeted by these allelic variants, sdrE2 would be expected to 
be observed at significantly higher frequencies than sdrE1. Given that most 
MSCRAMMs bind multiple ligands, we hypothesized that there is a secondary 
human host protein for SdrE that SdrE1 binds with higher affinity than SdrE2.  
A recently published study showed an interaction between SdrE1 and 
Factor H, an important regulator of the alternative complement pathway.20 After 
showing that SdrE1 binds Factor H with a high affinity that reflects what is likely 
a biologically relevant interaction and play a role in virulence, we were able to 
show that Factor H satisfies the hypothesis of a secondary ligand that SdrE1 
binds with significantly higher affinity than SdrE2. The original study published 
data that suggested the bound Factor H was functional and allowed for the local 
inhibition of the alternative complement pathway. 
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The many ways that S. aureus is able to inhibit and interfere with the 
complement system has been a virulence mechanism of growing interest over 
the past decade in our lab and others. While the importance of Factor H binding 
in comparison to Fg binding is still uncertain, we hypothesize that Factor H 
binding allows for greater virulence in the human host. This second function 
provides a rationale for the observation that sdrE1 is found more frequently than 
sdrE2 in staphylococcal isolates from humans.  
 
Fibrinogen binding is likely more important than BSP binding 
Bbp/SdrE2 was originally named for its ability to bind to bone 
sialoprotein. These original reports also found no fibrinogen binding. In 
contrast, our lab published that Bbp/SdrE2 binds to fibrinogen but has had 
difficulty to show an interaction of this MSCRAMM with BSP. We were able to 
acquire BSP purified from a human cell line, which had not previously been 
available to our lab and is important because it allows for the full post-
translational modification of the gene product. 
The ability of Bbp/SdrE2 to bind to BSP was weak as measured in ELISA-
type assay. Given these data and the fibrinogen binding data, it is unlikely that 
BSP-binding represents the major function of Bbp/SdrE2.  That fibrinogen 
binding is likely to be the more important mechanism of virulence lends 
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additional justification to a change in nomenclature to more adequately reflect 
the allelic nature of Bbp/SdrE2 and the similarities to SdrE1.  
 
PUTATIVE STAPHYLOCOCCAL VACCINE TARGET FOR ANIMALS 
It is clear that one of the underlying causes of the spread of antibiotic 
resistance amongst S. aureus isolates is the administration of antibiotics to 
livestock. European countries and the United States have started to take steps to 
limit the types of antibiotics that can be given to these animals, but this creates a 
hardship for farmers and veterinarians who need ways to combat bacteria and 
the variety of infections that they cause. Indeed, organizations representing 
farmers in the United States have already pushed back against the restrictions on 
antibiotic use, specifically cephalosporin use, that the FDA attempted to impose 
in 2007. After that failed attempt, the FDA is again attempting to put restrictions 
in place, albeit in a more limited manner.76 
An ideal way to combat these bacterial infections without the use of 
antibiotics would be a vaccine against S. aureus that could be used in animals. 
Ideal targets for this vaccine would be surface proteins, such as MSCRAMMs, 
that are shown to remain in the genome after the series of host adaptation steps 
occur. Although ClfA is an excellent putative target for a multivalent S. aureus 
vaccine in humans, the accumulation of truncation mutations in clfA genes from 
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LA-MRSA strains suggest that it is not expressed and displayed on the surface of 
LA-MRSA that has adapted to the animal host.  
Our work here shows that SdrE, could be an excellent target for a vaccine 
against LA-MRSA to be given to animals. sdrE1 is found in S. aureus  isolates 
taken from an array of animals from multiple continents and shows a 
functionality in in vitro experiments that strongly suggests a role in virulence in 
animal hosts. SdrE1 has already been identified as a putative vaccine target in 
humans and the generation of antibodies against both SdrE1 and SdrE2 has been 
published in the literature. One possible concern is potential for mutation in 
sdrE1 resulting in the generation of new variants by the bacteria due to selection 
pressures, but monitoring of the gene should allow a partial defense against this. 
sdrE1 has shown greater variability than sdrE2, but the sequence identity is still 
very high between genes. It is possible that the structural data discussed here 
could be used to identify regions with high degrees of similarity between SdrE1 
and SdrE2 that could be used as the basis of a vaccine effective against both 
variants.  
 
OTHER IMPLICATIONS FOR FUTURE RESEARCH 
The finding that the Lock domain of SdrE1/SdrE2 plays a large role in 
specificity and affinity of fibrinogen binding raises a number of important 
questions for future research. It is possible that more virulent S. aureus strains 
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evolve not only by the acquisition of a new gene or mobile genetic element, but 
also by accumulating mutations in small regions or subdomains that result in a 
significant alteration in the ligand binding profile. As greater understanding is 
gained of the domains within staphylococcal virulence factors that are critical for 
the binding phenotype, the need to monitor these shorts sequences will grow. 
Currently, most of the monitoring of sequence variations involves studying the 
sequences of antibiotic resistance genes. In the case of the SCCmec element, 
sequence variations in antibiotic resistance genes and recombinases are used for 
classification. Our data suggest that adhesins such as MSCRAMMs represent 
another important set of virulence factors that should be monitored in order to 
observe further host adaptation.  
One potential example of continued mutation in this region is SdrE1-
CC398. This clonal complex has been shown to play a major role in Livestock 
Acquired- MRSA infection. Given that SdrE2-N2N3 does not interact with 
fibrinogen from animals except for cows, it is not surprising that sdrE1 is 
overrepresented in animal staphylococcal isolates and is the allelic variant found 
in S. aureus CC398. However, it is possible that the variations within SdrE1-
CC398 provide an example of host adaptation to non-human species. The SdrE1-
CC398 amino acid sequence contains a T587N mutation that occurs within the 
Lock domain. Furthermore, over 50% of the other variations found in the ligand 
binding domain of SdrE1-CC398 are changes that result in the corresponding 
amino acid from SdrE2. These findings suggest that SdrE-CC398 has 
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accumulated mutations that result in an altered ligand binding profile, 
potentially including a greater capacity for binding fibrinogen from animals. 
While there are no changes within the SdrE-CC398 sequence previously 
established to affect binding, the changes can be mapped onto the SdrE1-N2N3-
Fg Peptide structure to provide greater understanding of how these variations 
could potentially affect the fibrinogen binding from animals.   
Another implication of this research regards the rapidly increasing pace at 
which large sequencing projects are being started. New, powerful sequencing 
techniques are being used to look at many isolates at once and perform 
comparative genomic analyses. As sequencing capabilities make large scale 
sequencing projects on the order of 103 genomes possible, there are heretofore 
unanswered questions regarding how to adequately and appropriately to analyze 
genomic data that is orders of magnitude larger than what was available 
previously. Studies that have been published to date using these approaches 
have focused on data points such as the presence, lack of or movement of large 
mobile genetic elements. Examples include φSa3, which has been found in 
staphylococcal isolates from avian strains and contains genes that have been 
putatively identified as virulence factors for avian species based on similarity 
studies. Furthermore, these studies have noted the accumulation of stop codons 
or disappearance altogether of genes like clfA, clfB, and hlaB.  
However, sequencing data alone cannot provide the rationale for the 
observed differences in allelic frequency in sdrE in animal and human 
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staphylococcal isolates. While all of the residues that play a role in the differing 
phenotype of SdrE1 and SdrE2 have yet to be elucidated, our data clearly show 
that the Lock domain is critically important for binding and that variations 
within this region can result in phenotypic differences. The sequence changes 
between the variants were not changes that would clearly result in a change in 
phenotype based on in silico analysis. However, through careful biochemical 
experiments and structural data, this domain was elucidated. In this instance, 
the biochemical data has provided information to explain the sequencing data. 
And now, this information can be used to more capably interpret future 
sequencing data.  
SdrE is not the only staphylococcal virulence factor that has been shown 
to accumulate mutations that result in a change in binding profile. In 
staphylococcal infections of implanted cardiovascular devices, FnBPA 
accumulates polymorphisms that are responsible for a greater affinity for 
fibronectin as measured by atomic force microscopy.30 This provides another 
example of host adaptation by S. aureus, albeit over a shorter time frame and on 
a smaller scale than seen with the CC398 studies.  
Similar to allelic variants SdrE1 and SdrE2, SCIN proteins are 
staphylococcal complement inhibitors that have three active members in the 
genome. Despite a similar overall structure and targeting of the same spots on 
C3 convertase, there were key differences between SCIN-A and SCIN-B in 
specific residues that bound C3 convertase and the manner in which they bound.  
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Structural data revealed the basis for a lack of SCIN-D binding. Together, these 
examples speak to the need to understand the biochemical changes that 
sequence variations can cause at the molecular level. 
To gain a better understanding of the effects of sequence variations that 
are found in large scale whole genome sequencing projects, biochemical 
approaches will be necessary.  However, many of the approaches used here 
require large amounts of highly purified protein and a significant amount of 
time. In order to keep pace with the rapidly expanding database of whole 
genome sequences and the variations in virulence factors that will be discovered, 
there will be a greater need for high throughput biochemical approaches to 
examine the phenotypic effects of small variations and mutations.  
It is facile to think of Staphylococcus aureus as having a static, if diverse, set 
of virulence factors that allow for classification and eventual targeting by 
antibacterial or vaccine approaches. S. aureus should instead be seen as an 
rapidly evolving bacteria that has had decades, if not longer, to adapt to the 
colonization and infection of the human host. In the past, the absence, presence 
and emergence of new genes were the focus of studies of S. aureus virulence. 
However, the rapidly growing capabilities of sequencing technology will result 
not just in a larger data set of whole genome sequences, but greater potential to 
pinpoint small sequence changes that result in significant changes in binding or 
virulence. If high throughput biochemical techniques are developed to pair with 
the large data sets of whole genome sequences, we will gain far greater 
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understanding of both the mechanisms of virulence of S. aureus and the ways in 
which it is currently adapting and evolving to challenge the defenses of the non-
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